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ABSTRACT 
 
 
Neoplastic diseases have become one of the most important causes of death in the 
world. In USA, cancer is the second cause of death after the cardiovascular diseases. 
Therefore, the research, the discovery and the development of new compounds with 
antitumoral activity have become one of the most important goals in medicinal 
chemistry, also trying to make a selective toxicity towards the diseased or cancer cells, 
thus not involving the healthy cells. Many therapeutic approaches are available for the 
treatment of cancer in clinical use: surgery, radiotherapy are used for localized cancer; 
chemotherapy, hormone-therapy and immunotherapy are considered useful, as systemic 
treatments, for leukemia and metastatic tumours. In the chemotherapy a high number of 
molecules interacts with nucleic acids like groove binders, alkylating and intercalator 
compounds. The molecules that belong to the latter class, interact with DNA by 
intercalation in the base pairs through van der Waals interactions, hydrogen bonds, 
hydrophobic and/or charge transfer forces. Therefore, these molecules have attracted, 
during their development, particular attention as chemotherapeutic agents in medicinal 
chemistry because the consequences of DNA intercalation by exogenous molecules lead 
to a significant modification of the DNA structure and may result in a hindered or 
suppressed function of the nucleic acid in physiological processes. But the clinic 
application of these compounds has shown some problems such as multidrug resistance 
(MDR), and secondary and/or collateral effects. These shortcomings have motivated the 
search of new compounds to be used either in place of, or in conjunction with, the 
existing molecules. 
Condensed poly(hetero)aromatic compounds are usually regarded as representative 
DNA intercalators, especially if they contain electron-deficient or charged aromatic 
cores in the structure. Measurement of the binding constant and biological activity of 
DNA-intercalator complexes and QSAR studies lead to the conclusion that there should 
exist a relationship between cytotoxic activity and binding force. Otherwise, 
cytotoxicity is not only dependent on the ability to interact with DNA, since there are 
many DNA intercalators that are incapable of working as cytotoxic agents: to be 
effective, a drug must first overcome many barriers, including metabolic pathways, 
cytoplasmatic and nuclear membranes. Cytotoxicity could be also a consequence of the 
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poisoning of topoisomerases, enzymes that are directly involved in DNA recognition 
and that regulate DNA topology. They induce cytotoxicity when they act as poisons 
towards the enzymes by stabilizing the ternary DNA-intercalator-topoisomerase 
complex in such a way that the enzymatic process cannot continue forward or 
backward. This complex is detected by the cell as a damaged portion, which triggers a 
series of events such as cell apoptosis. 
Some compounds, called photonucleases, which induce DNA damage after UV-VIS-
irradiation, have become interesting; while the association of cationic dyes to DNA is a 
reversible process, the DNA damage, which frequently occurs on irradiation of ligand-
DNA complexes, is often irreversible. The latter DNA damage may lead to cell death or 
mutation, and must be avoided in healthy systems. However, this photoinduced DNA-
damage may be applied in photochemotherapy to remove unwanted cells.
 
Among the compounds investigated along these lines, the quinolizinium derivatives, 
such as coralyne and the related molecules, have attracted particular attention. They are 
arenes containing quaternary bridgehead nitrogen atom and have been shown to bind to 
DNA and may be employed as a central unit in DNA-targeting drugs. During the studies 
of the influence of the substituition pattern of quinolizinum derivatives on their 
intercalation with DNA, it has been shown that the chemical structure of the tetracyclic 
naphtho[1,2-b]quinolizinium bromide 2 has interesting properties with respect to the 
binding to nucleic acids. In particular, these intercalators may exhibit a stronger 
interaction with nucleic acids as compared with the tricyclic benzo[b]quinolizinium 1: 
the additional benzene moiety extends the surface of the planar chromophore and 
increases the  stacking between the dye and the DNA bases, resulting in higher binding 
constants. Other important aspects are represented by the photobiological properties: it 
was shown that an efficient DNA-strand cleavage is photoinduced by the naphtho[1,2-
b]quinolizinium bromide 2. 
The compounds synthesized and analyzed in this project were 3-aryl-substituted-
naphtho[1,2-b]quinolizinium derivatives; then studies about the DNA-binding 
properties and cytotoxic activity were carried out. The investigation of these compound 
allows to evaluate the effects of the extension of  system, by the introduction of fourth 
aromatic ring, and the effects of the substituent in position 3. This position was chosen 
for structural analogy with some tricyclic benzo[b]quinolizinium 1, with better 
biological activity with respect to the not-substituted compound. After these, 
experiments in comparison to the naphtho[1,2-b]quinolizinum bromide 2, without 
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substituents in position 3, to investigate preliminary molecular target (topoisomerase I 
and II), to attempt a structure-relactionship-activity and finally photobiological tests will 
be carried out. 
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RIASSUNTO 
 
 
Le neoplasie risultano essere una delle più importanti cause di morte nel mondo: negli 
Stati Uniti il cancro rappresenta la seconda causa di morte dopo le malattie 
cardiovascolari. Quindi la ricerca, la scoperta e lo sviluppo di nuovi composti a 
potenziale attività antitumorale è considerato uno dei più importanti obiettivi in campo 
della chimica farmaceutica, cercando anche di distinguere in termini di citotossicità le 
cellule sane da quelle cancerose e malate. Ad oggi, molti approcci terapeutici sono 
disponibili per il trattamento del cancro in ambito clinico: chirurgia, radioterapia sono 
usate nel trattamento di tumori localizzati; chemioterapia, terapie ormonali, 
immunoterapia si sono invece rivelate utili nella cura di leucemia e tumori metastatici. 
Nell’approccio chemioterapico un alto numero di molecole interagisce con gli acidi 
nucleici come groove binders, agenti alchilanti e intercalanti. Le molecole che 
appartengono a quest’ultima classe interagiscono con il DNA intercalandosi appunto fra 
le coppie di basi attraverso interazioni di Van der Waals, legami idrogeno, legami 
idrofobici e/o interazioni di carica. Molte di queste molecole hanno suscitato particolare 
interesse durante il loro sviluppo come potenziali agenti chemioterapici perché è noto  
che una conseguenza dell’intercalazione da parte di molecole esogene nella doppia elica 
è proprio una modifica strutturale e chimico-fisica della struttura che vede come 
risultato un’alterata o arrestata funzione del DNA nei processi fisiologici. Ma 
l’applicazione clinica di questi composti ha mostrato problemi in termini di insorgenza 
di resistenze (MDR), effetti secondari o collaterali. Questi inconvenienti hanno spinto 
alla ricerca di nuovi composti che potessero sostituire o migliorare i composti già 
esistenti. 
I poli(etero)cicli aromatici condensati sono solitamente considerati buoni agenti 
intercalanti, specialmente se nel core aromatico presentano cariche positive. 
Gli studi sulla valutazione quantitativa della costante di binding e sull’attività biologica 
dei complessi DNA-agenti intercalanti e di QSAR hanno portano alla conclusione che 
potrebbe esistere una relazione tra attività citotossica e forza di binding. Comunque la 
citotossicità non è soltanto dipendente dall’abilità a interagire con il DNA, dal momento 
che alcuni intercalanti si sono rivelati anche non citotossici: infatti per poter esercitare il 
suo effetto, un farmaco deve prima passare barriere, vie metaboliche, membrane 
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citoplasmatiche e nucleari. La citotossicità può anche essere conseguenza dell’azione di 
veleno contro le topoisomerasi, enzimi direttamente coinvolti  in processi che 
coinvolgono gli acidi nucleici in fondamentali steps della crescita cellulare e regolano la 
topologia del DNA. Gli intercalanti del DNA possono esplicare un’azione citotossica 
attraverso stabilizzazione del complesso DNA-intercalatore-topoisomerasi in modo che 
il ciclo biochimico venga bloccato. Questo complesso con il DNA danneggiato poi può 
essere riconosciuto dalla cellula che attiva una serie di vie biochimiche che portano 
all’apoptosi. 
Si sono rivelati anche interessanti quei composti, chiamati fotonucleasi, che inducono 
danno al DNA dopo irradiazione con luce UV-VIS; mentre l’associazione di cationi 
organici al DNA è un processo reversibile, il danno al DNA generato dopo irradiazione 
del complesso ligando-DNA è spesso irreversibile e questo può portare a morte 
cellulare, mutazioni che dovrebbero essere evitati in sistemi sani. Comunque, un 
fotodanno al DNA potrebbe essere applicato in fotochemioterapia al fine di rimuovere 
cellule malate. 
Tra i composti studiati in tutto questo contesto, i derivati del chinolizinio, come la 
coralina e molecole correlate, hanno suscitato particolare interesse. Essi constano di 
anelli aromatici condensati con una carica positiva sull’azoto quaternario e hanno 
mostrato di legare il DNA. Durante gli studi sulle modifiche chimiche del chinolizinio 
in termini di legame al DNA, è stato mostrato che la struttura chimica tetraciclica del 
nafto[1,2-b]chinolizinio bromuro 2 presenta interessanti proprietà di binding agli acidi 
nucleici: in particolare viene osservata una forte interazione se comparata al derivato 
triciclico benzo[b]chinolizinio 1, dovuta all’addizione del quarto anello aromatico che 
estende la superficie planare del cromoforo ed aumenta le interazioni  tra il composto e 
le basi del DNA. Altro aspetto importante è rappresentato dalle attività fotobiologiche: è 
stato mostrato che esiste un efficiente taglio del DNA fotoindotto appunto dal nafto[1,2-
b]chinolizinio bromuro 2. 
In questo progetto di ricerca sono stati analizzati e sintetizzati derivati 3-aril del 
nafto[1,2-b]chinolizinio; e successivamente sono stati effettuati studi per determinare la 
tipologia di binding al DNA e l’attività citotossica. Particolare attenzione è stata riposta 
sulla valutazione dell’effetto dell’introduzione del quarto anello aromatico e della 
sostituzione in posizione 3. Quest’ultima posizione è stata scelta in analogia a alcuni 
derivati del triciclico benzo[b]chinolizinio 1 con migliore attività biologica rispetto alla 
molecola di partenza. Successivamente prendendo come riferimento il nafto[1,2-
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b]chinolizinio bromuro 2, senza quindi sostituenti in posizione 3, si sono condotti studi 
preliminari sull’identificazione, oltre agli acidi nucleici, di un probabile target 
molecolare (topoisomerasi I e II); si è cercato di ipotizzare una relazione struttura-
attività e infine di valutare l’attività fotobiologica.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1. Introduction 
3 
 
1.1 CANCER AND CHEMOTHERAPY 
 
Cancer derives from modifications of the genes responsible for cell growth and repair.  
Normally, healthy cells are under strict control for growth and differentiation. Cells 
divide and proliferate under influence of various growth stimulators and are subject to 
arrested growth (senescence) and programmed cell death (apoptosis). In cancer, these 
regulatory processes have gone awry, and cells grow and divide uncontrollably, losing 
the structure due to the inability to adequately differentiate. Furthermore, the 
uncontrolled cell division is accompanied by deactivation of the processes of cell death 
even leading to genetic alterations.
1
 The factors that can cause and generate the cancer 
are numerous: genetic factors, ultraviolet (UV) and ionizing radiations, chemical 
carcinogens, biological carcinogens, such as infections by virus (Hepatitis B Virus, 
Human Papilloma Virus), bacteria (Helicobacter pylori).
2 
Anyway all these causes lead 
to an alteration of the expression of proto-oncogenes whose products control the normal 
life of the cell; when these genes mutate to become oncogenes, through various steps, 
leading to the formation of a tumor cell. At the same time, tumor suppressor genes can 
also be inhibited (p53, p-21). In USA every year, 1,3 million cases of cancer are 
diagnosed, provoking almost 570.000 deaths.
3
  
Therefore, the research, the discovery and the development of new compounds with 
antitumoral activity have become one of the most important goals in medicinal 
chemistry.  
Currently, there many therapeutic approaches are for the treatment of cancer: surgery 
and radiotherapy, useful techniques to remove localized cancer; systemic treatments, as 
chemotherapy, hormone-therapy and immunotherapy, useful for leukemia or metastatic 
tumour. Chemotherapy is based on the use of chemical compounds, which, by a 
cytotoxic action, can produce antiproliferative effects. In order to have an anticancer 
drug without side effect, many researchers try to find and to identify specific target, 
because there are little differences between cancer and somatic cells. Another increasing 
problem is the chemoresistance due to molecular changes of specific pump or particular 
membrane protein, such as the class of MDR (Multi Drug Resistence Proteins), which 
decrease the therapeutic action of drugs; the classic form of MDR is due to an increased 
activity of P-glycoprotein (Pgp), encoded by the human MDR1 gene. This glycoprotein 
is located in the plasma membrane and can extrude a range of hydrophobic natural 
1. Introduction  
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product drugs from the cell against a concentration gradient. An increase in Pgp activity 
can result in lowered intracellular drug concentration and, hence, in drug resistance.
4,5 
So, at the moment, polychemotherapy is the main strategy against.
6
 
The anticancer agents can be classified on the basis of their different mechanism of 
action.
1
 
 
Alkylating agents 
They form a covalent binding to DNA involving base modifications through alkylation 
by a nucleophilic attack of N7 of a guanine of DNA to the electrophilic part of the drug 
forming a monoalkylated adduct. Some agents (nitrogen mustards) can also bind two 
bases of DNA involving two guanine (N7) residues determining the formation of DNA-
crosslink between two complementary strands (interstrand) or within a strand of DNA 
(intrastand), as the case of cisplatin. All these reactions induce a irreversible damage in 
the double helix and to DNA replication.
1
 
 
Antineoplastic antibiotics 
They belong to a high number of natural or semi-synthetic compounds which block 
DNA-transcription inducing breaks to the DNA structure or inhibiting important 
enzymes for the DNA-replication process. They can interact directly with DNA, 
intercalating into double helix in the base pairs, by a strong non-covalent interaction. 
Some of these compounds inhibit the topoisomerase II, enzyme responsible for 
maintaining the correct structure of DNA.
1
  
In this class, some compounds, called “code reading agents”, can be considered: they 
are able to recognize and bind specific sequence of the double helix of DNA by non-
covalent interaction. As mentioned before, intercalators and groove binders belong to 
this class of compounds. Intercalation occurs when ligands of an appropriate size and 
chemical nature fit themselves in between base pairs of DNA. These ligands are mostly 
polycyclic, aromatic, and planar
7
 and they induce local structural changes to the DNA 
strand (such as lengthening of the DNA strand or twisting of the base pairs), leading to 
functional changes such as the inhibition of transcription and replication and DNA 
repair processes. Formed complexes deform and unwind the DNA, thus they can be 
applied in the chemotherapeutic treatment  to inhibit DNA replication in rapidly 
growing cancer cells. Examples include doxorubicin and daunorubicin (used in 
treatment of Hodgkin's lymphoma), and dactinomycin (used in the treatment of Ewing's 
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Sarcoma). Groove binders are usually cationic molecules that bind in the minor or 
major groove of DNA.
8 
 
Antimetabolic agents 
They act as false substrates: the chemical structural analogy with one of the metabolites 
normally present in the cells is used to induce a block of the enzymatic system 
(polymerases) or the synthesis of inactive substances or with another function, 
provoking a stop or the destruction of the cancer proliferative apparatus. These 
compounds are not selective, although the malignant cells have an intensive 
proliferation. Some examples of these agents are the antagonist of the folic acid 
(metotrexate) and the analogous of the purinic (6-mercaptopurine) and pyrimidinic 
bases (5-fluorouracil). 
 
Antimitotic agents  
They are natural alkaloid or semi-synthetic compounds which interfere with the normal 
process of polymerization-depolymerization of heterodimer α-β of the tubulin inducing 
a damage to structure of microtubules and causing cell death. Some molecules of this 
class are taxol and the alkaloids of Vinca (vinblastine, vincristine).
1
 
 
Quadruplex-interactive agents 
There are special sequences in DNA that can form secondary DNA structure; there are 
some of these that are rich in guanine and are capable of forming a four-stranded 
structure (G-quadruplex structure), further stabilized by the presence of a cation, 
especially potassium, which sits in a central channel between each pair of tetrads.
9 
Telomeres and promoters with polypurine-rich strand can induce G-quadruplex and the 
helicases control the equilibrium between double-strand and G-quadruplex. The drugs 
can inhibit helicases or facilitate the formation of new quadruplex. They can also 
sequester newly formed G-quadruplex (telomestatin).
10
 
 
Topoisomerase inhibitors 
DNA is also considered a scaffold on which DNA-binding proteins assemble. These 
proteins are involved in replication, transcription, recombination and repair, crucial 
processes for normal cellular growth. So a good strategy is blocking the binding 
protein-DNA. Some agents can act inactivating enzymes, as topoisomerase I (i.e., CPT) 
1. Introduction  
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or  topoisomerase II: some of these (i.e., doxorubicin) can also binding DNA, while 
others can bind only on topoisomerase (i.e., etoposide), not interfering directly with 
other DNA processes.
1,11,12
 
 
Hormone therapy 
Glucocorticoid compounds are used as antitumoral agents in leukemia and lymphoma. 
Antiestrogens (tamoxifene) or antiandrogens (cyproterone), can be used for hormone-
dependent cancer (breast and prostate carcinoma).
1 
 
1.2 DNA 
 
Deoxyribonucleic acid (DNA) is a nucleic acid that contains the genetic instructions 
used in the development and functioning of all known living organisms and some 
viruses. The main role of DNA molecules is the long-term storage of information. It 
contains the instructions needed to construct other components of cells, such as proteins 
and RNA molecules. The DNA segments that carry this genetic information are called 
genes, but other DNA sequences have structural purposes, or are involved in regulating 
the use of this genetic information. Within cells, DNA is organized into long structures 
called chromosomes. During cell division, these chromosomes are duplicated in the 
process of DNA replication, providing each cell its own complete set of chromosomes. 
Eukaryotic organisms store most of their DNA inside the cell nucleus and some of their 
DNA in organelles, such as mitochondria or chloroplasts.
13 
All the functions of DNA depend on interactions with a large number of enzymes: the 
polymerases that copy the DNA base sequence in transcription and DNA replication;
14
 
the topoisomerases to maintain the correct topological structure;
12
 the nucleases and 
ligases,
15,16
 used in DNA repair and genetic recombination; helicases for most processes 
where enzymes need to access the DNA bases.
17
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1.2.1 CHEMICAL STRUCTURE AND FORMS OF DNA 
 
The double helical of DNA is composed by a chemical structure of nucleic acids that 
draw a linear polymer of nucleotide whose sugars are bonded through phosphodiester 
groups-bridges at 3’ and 5’ position. At physiologic pH, the phosphodiesters are acidic, 
so they show negative charges that determine the polyanionic structure. DNA is 
composed by the same percentage of nucleotides adenine (A), thymine (T), guanine (G), 
cytosine (C) (Figure 1.1).  
 
 
 
 
 
 
Figure 1.1 Schematic representation of nucleotides and sugar bonded to phosphodiester groups. 
 
DNA is a structurally flexible polymorphic molecule that can adopt a variety of 
conformations. The main family of DNA forms identified are the right-handed A- and 
B-forms and the left-handed  Z-form
 
 (Figure 1.2 and Figure 1.3).
18-20
 But there are also 
many other structures like loops, hairpins or cruciforms, and higher order structures like 
triplexes,
21
 quadruplexes
9
 are known to exist. 
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Figure 1.2 Schematic representation of B-, A-, Z- and triplexes structures of DNA 
 
 
 
 
 
Figure 1.3 Parameters of A-, B- and Z-DNA double helices. 
 
The A-form of DNA is a right-handed double helix, with a short and compact helical 
structure. It can occur only in DNA-RNA hybrid helices and by regions of double-
stranded RNA. A-DNA is characterized by base pairs that are highly inclined and 
displaced away from the helix axis and a helical repeat of 11 bp per turn
22 
 and the base 
pairs tilt to 19 degrees with respect to helix axis. This from has a shallow minor groove 
and a very deep major groove. In addition the sugar has the C3’-endo conformation.20 
The Z-form is a left-handed double helical structure and occurs in part of DNA rich in 
guanine and cytosine. The Z-DNA is long and thin and the bases are relatively farther 
 1. Introduction 
9 
 
from the helix axis, creating a deep narrow minor groove, while the major one is not 
properly a groove. Formation of this structure is generally unfavourable, although 
certain conditions can promote it, such as alternating purine-pyrimidine sequence 
(especially poly(dGC)2), negative DNA supercoiling and some cations (all at 
physiological temperature, 37°C, and pH 7.3-7.4).
23 
Z-DNA is a transient structure that 
is occasionally induced by biological activity and then quickly disappears.
24
 
 
The B-form of DNA is the most common structure,  the native conformation of DNA in 
solution under physiological conditions. It is a right-handed form and the two 
polynucleotide chains run in opposite directions (antiparallel). The aromatic bases are 
located internally in the helix, while the phosphate backbone are externally exposed. 
The sugars are 2’-deoxyribose and are bonded with bases in 1’ position and with 
phosphates in 5’ and 3’ positions (Figure 1.4). The plane of the bases are perpendicular 
respect to the double helix axis. 
 
 
 
Figure 1.4 Schematic representation of nucleotides and sugar bonded to phosphodiester groups and 
chemical structure of DNA helix. 
 
The ideal B-DNA has a pitch of 34 Å, because are involved 10 base pairs (bp) per turn 
and the aromatic rings have a thickness of 3,4 Å. Every base pair axis turn of 36° 
respect to the axis of the adjacent pairs (Figure 1.4). Bases of opposite strands are 
coupled through hydrogen bond interactions; the adenine of one strand is coupled to the 
thymine in the opposite one and any guanine interacts with cytosine (Figure 1.5). 
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Figure 1.5 Hydrogen bonding in the A·T and C·G Watson-Crick DNA base pairs. 
 
B-DNA presents two external grooves of different size generated by the structure of the 
two strands of the helix, between the ribose-phosphate backbone and the inner surface 
of macromolecule (Figure 1.6 and Figure 1.7): the bases in these grooves are exposed to 
the solvent and this is important because they are available to specific interaction with 
chemical molecules. 
 
 
 
Figure 1.6 Chemical representation of major and minor groove. 
 
The major groove is wide and easily accessible to proteins, while minor groove is 
narrow; this conformation is favoured at high water concentrations.  
 
 
Figure 1.7 B-DNA double helix with the minor and major grooves highlighted. 
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In order to reduce he tension of sugar ring, four atoms remain almost co-planar and the 
fifth one stays slightly out of the plane. This determines two conformations: if the out-
of-plane atom is on the same side of C5’ substituent, it is called endo; if it is on the 
opposite side of C5’ it is called exo. Generally the out-of-plane atoms are either C2’ and 
C3’ (Figure 1.8).  
 
 
Figure 1.8 Schematic representation of C2’-endo and C3’-endo sugar conformation. 
 
With respect to the glycosidic bond, purine residues may assume two sterically possible 
conformation, syn and anti (Figure 1.9), while for pyrimidines only the anti is 
acceptable (in the syn conformation the C5’ atom of sugar would be too close to C2 
substituent of base). Generally all bases of B-form DNA are in anti conformation.  
 
 
 
Figure 1.9 Structures of syn and anti nucleoside conformations. 
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1.3 INTERACTION AND BINDING MODES OF 
ORGANIC MOLECULES WITH DNA 
 
The interaction between external molecules and the nucleic acids and the formation of a 
complex leads to important modifications of the structure of the DNA and may have an 
important influence on the physiological function of the DNA, such as the suppression 
of the DNA replication and gene transcription leading to cell death, useful in an 
antiproliferative approach. So an important goal is the design of DNA-binding 
molecules which selectively bind to DNA in unwanted cells and lead to cell death 
without damaging the healthy cells. In these years, many investigations have been 
performed to clarify different aspects of the association process of large and small 
molecules with DNA identifying several classes of DNA-binding molecules: some 
macromolecules as the proteins, after association with DNA, constitute important steps 
in the gene-transcription process; the oligosaccharides, organometallic complexes and 
cationic organic dyes.
7,25,26 
There are three binding modes between a molecule and DNA (Figure 1.10): external 
binding due to attractive electrostatic interactions between a positively charged 
molecule and the negatively charged phosphate backbone of the DNA and it occurs on 
the external surface of the double helix,
27
 and the most common minor or major groove 
binding and intercalation.
25 
 
 
 
 
 
Figure 1.10 Binding modes of small molecules with DNA. 
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1.3.1  GROOVE BINDING  
 
The DNA helix has two grooves of different size, the minor and the major grooves, 
which can represent binding sites for guest molecules. Large molecules, like proteins, 
prefer to bind to the major groove, while small ligands prefer the minor groove. The 
chemical structure of groove binders presents two aromatic or heteroaromatic rings 
whose connection allows conformational flexibility and so the molecule can fit into the 
groove. Additional functional groups can be required to improve the interaction, that 
usually occurs by hydrogen bonding and hydrophobic.
28
 Typical minor-groove binders 
are Hoechst 33258, netropsin (Figure 1.11). Most groove binders have selectivity and 
affinity toward AT-rich region because in this area the electrostatic attraction is higher 
than in GC-rich one and furthermore, the grooves, which consist of GC base pairs, are 
sterically hindered by the guanine amino functionality at C-2 and its hydrogen bond 
with the C-2 carbonyl group of cytosine. Anyway, the groove binders with a structure 
that can form strong attractive interactions with the guanine amino group can also bind 
GC-rich grooves.
25
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Figure 1.11 Examples of minor-groove binders. 
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1.3.2  INTERCALATION  
 
In DNA helix, the bases are located in an almost coplanar arrangement. It has been 
shown the planar polycyclic aromatic molecules to intercalate between two base pairs
25 
through a binding mode realized by dipole-dipole interactions and  stacking29 of the 
ligand with the aromatic nucleic bases. The intercalation has a significant influence on 
the DNA structure because it causes DNA unwinding, leading to a lengthening of the 
helix of more than 3.4 Å, along with a significant change of deoxyribose conformation.  
In order to describe theoretically the intercalation, this “neighbour exclusion principle” 
has to be considered. It can be used as general rule, but not totally explained; a 
hypothesis could be that the structural changes of DNA on intercalator lead to limited 
access to the neighbouring binding pocket for steric reasons.
25 
The intercalators have an appropriate size and chemical nature to fit themselves in 
between base pairs; they are mostly polycyclic (at least two annellated aromatics rings), 
aromatic, and planar, and therefore often make good nucleic acid stains.
7
 In most cases, 
a positive charge is required for an appropriate binding affinity, in order to enhance the 
attractive ionic interactions between the cation and the phosphate backbone. So it’s easy 
to think that the pH of the environment has a significant influence on the DNA-binding 
properties of such ligands. It is interesting the possible introduction of the cationic 
nitrogen atom as a bridgehead between two annelated rings, as the quinolizinium ion 
and related derivatives.
30,31
 In these cases, the charge is independent of the pH of the 
environment. The compounds analyzed in this project are derivatives belong to the 
family of naphthoquinolizinium ion.  
 
The structural modifications after the intercalation can lead to functional changes, often 
to the inhibition of transcription and replication and DNA repair processes, which 
makes intercalators potent mutagens. For this reason, DNA intercalators are often 
carcinogenic, (proflavine
7
, ethidium bromide,
26
 protoberberine
32
) (Figure 1.12). 
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Figure 1.12 Examples of intercalators. 
 
DNA binding of an intercalator and its biological activity can be connected. However, 
cytotoxicity is not only dependent on the ability to interact with DNA because to be 
effective, a drug must first overcome many barriers, such as cytoplasmatic and nuclear 
membranes. When it is in the nucleus, it can form a complex with a relatively long half-
life. Cytotoxicity could also be a consequence of the binding with some essential 
proteins, associated with double helix, as topoisomerase I and II, enzymes involved in 
particular steps of the cellular growth and of cell cycle, in which the topology of the 
DNA plays a significant role. A damage of DNA usually can lead to a series of events 
that involve p53 protein, and subsequent apoptosis. Anyway, many efforts are still made 
to discover new compounds, in order to improve the selectivity and to overcome drug 
resistance. 
 
 
 
 
 
N 
+ 
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1.3.3 EVALUATION AND DETERMINATION OF BINDING 
MODE 
 
In a host-guest complex, the physical properties of the DNA and the intercalator or 
groove binder are usually significantly different from those of the uncomplexed host 
and guest molecules. Complex formation can therefore be assessed by monitoring a 
change of a particular physical property. The extent of this change usually depends on 
the binding mode and, thus, enables intercalators and groove binders to be 
distinguished. If the focus is on the properties of the DNA molecule, hydrodynamic 
methods such as the viscosity or the sedimentation coefficient are helpful for 
monitoring the association process. The thermodynamic stability of the DNA helix is 
also influenced by complex formation, so association with a guest molecule might also 
be determined by measuring a change of the melting temperature. Hydrodynamic 
methods are especially reliable and helpful for distinguishing the binding mode, because 
on intercalation the observed change of the DNA structure and thus the change of the 
viscosity or the sedimentation coefficient is relatively large whereas groove binding 
leads to marginal structural changes only. Absorption and emission spectroscopy are 
also useful tools for monitoring DNA-binding processes. The interaction of dyes, 
especially, with DNA can be conveniently observed by these methods, because their 
absorption and emission properties change significantly on complex formation. Along 
with straight forward determination of absorption or emission intensity and wavelength, 
several variations and additional experiments are possible. For example, absorption of 
circularly or linearly polarized light can be used in CD and LD spectroscopy to gain 
further knowledge of the orientation of the dye molecule relative to the DNA. It should 
be noted that determination of the binding mode needs to be performed with much care 
and that the use of only one method can lead to misinterpretation. In critical reviews, it 
has been pointed out that only a combination of selected methods provides sufficient 
information to draw conclusions about the mode of binding. Anyway spectrometric 
methods are considered useful and practical tools for study of the DNA-binding 
properties of organic dyes.
25 
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1.4 CELL CYCLE 
 
The cell cycle is an ordered set of events that lead to biochemical modifications of the 
cell, culminating in cell growth and division into two daughter cells. It is based upon the 
rotation of two principal periods: interphase and mitosis (Figure 1.13). The first one can 
be divided into four steps: G0 (Gap or growth 0), G1 (Gap or growth 1), S (synthesis) 
and G2 (Gap or growth 2): 
                 
 G0 phase: is a period of the cell cycle in which cells exist in a quiescent state. 
G0 phase is viewed as either an extended G1 phase, where the cell is neither 
dividing nor preparing to divide, or a distinct quiescent stage that occurs 
outside of cell cycle. On occasion, a distinction in terms is made between a G0 
cell and a quiescent cell (heart muscle cells, neurons i.e.,) which will never 
enter in G1 phase, whereas other G0 cells may. Cells enter the G0 phase from a 
cell cycle checkpoint in the G1 phase, such as a restriction point. In order to 
overcome it, growth factors or nutrients are required. In absence of these, the 
cells remain quiescent without growing and dividing. If these are present and 
correct, the cells may re-enter in the cycle and subsequently divide. 
 
 G1 phase: during this phase the biosynthetic activities of the cell resume at 
high rate. The cells increase in size, synthesizing RNA and proteins, which will 
be useful for DNA replication.  
 
 S phase: it starts with DNA synthesis; the amount of DNA in the cell has 
effectively doubled; when it is complete, all of the chromosomes have been 
replicated. Rates of RNA transcription and protein synthesis are very low 
during this phase. 
 
 G2 phase: during the gap between DNA synthesis and mitosis the cell 
continues to grow and produces new proteins, involved principally in the 
production of microtubules, required in the next process of mitosis. Inhibition 
of protein synthesis during G2 phase prevents the cell from undergoing mitosis.  
1. Introduction  
18 
 
 Mitosis or M-phase: it can be divided into five stages: prophase, 
prometaphase, metaphase, anaphases and telophase and it is the process by 
which a eukaryotic cell separates the chromosomes in its cell nucleus into two 
identical sets in two nuclei.
33
 It is followed by cytokinesis, during which there 
is the division of the cytoplasm, organelles and cell membrane into two 
daughter cells containing roughly equal shares of these cellular components.
 
There is also here a checkpoint (Metaphase checkpoint) that ensures the cell is 
ready to complete cell division.
34
 
 
 
 
 
 
 
Figure 1.13 Schematic representation of cell cycle. 
 
 
1.4.1 CELL CYCLE REGULATION 
 
The cell cycle contains numerous checkpoints that allow the cell to check for and repair 
DNA damage,
35
 regulate the progress of cell cycle and they are designed to ensure that 
damaged or incomplete DNA is not passed on the daughter cells. The cell cannot 
proceed to the next phase until checkpoint requirements have been met.  
The control is of regulated by cyclins and cyclin-dependent kinases (CDKs):
36
 cyclins, 
with their bound and activated CDKs, function during distinct stages of the cell cycle. 
The level of each cyclin independently increases or decreases within the phases of the 
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cycle. Cyclin/CDK complexes phosphorylate specific protein substrates to move the cell 
through the cycle with activation of DNA synthesis (in late G1 and S), and formation of 
the structural components associated with mitosis (in late G2 and M). So, two important 
checkpoints
34
 are determined: G1/S that ensures that everything is ready for DNA 
synthesis and G2/M that ensures if the cell can proceed to enter M-phase and 
consequently division. The periodicity of the cyclins, mediated by their synthesis and 
subsequent proteolytic degradation, ensures the well-delineated transitions between cell 
cycle stages.
37
 
Furthermore, the p53 protein plays an important role in triggering of the control 
mechanisms at both checkpoints. A disregulation of the cell cycle components may lead 
to tumor formation. Some genes like the cell cycle inhibitors (p53), mutating, may 
cause an uncontrollably cell proliferation, forming a tumor. So, the cell cycle machinery 
and components of checkpoint pathways have already provided a large number of 
targets for novel antineoplastics.
38 
 
 
1.5 TOPOISOMERASE I AND II 
 
The topological state of DNA in the cell is modulated by enzymes known as DNA 
topoisomerases, essential enzymes that act (by over- and underwinding, knotting, 
tangling) in connection with a number of nuclear processes, such as replication, 
transcription, chromatin remodeling, chromatin condensation/decondensation, 
recombination and repair. Topoisomerases maintain genomic integrity during this 
process by forming covalent attachments between active site tyrosyl residues and the 
terminal DNA phosphates that are generated during the cleavage reaction. As a 
consequence of their reactions mechanism, these enzymes alter only the spatial 
orientation of the double helix: the chemical structure of DNA product generated by 
them is identical to those of their initial substrate molecules.
39-41.
  
Cells encode two classes of topoisomerases that are distinguished by their catalytic 
mechanisms. Type I topoisomerases act by generating a transient single stranded break 
in the double helix, followed by either a single-stranded DNA passage event or 
controlled rotation about the break. As a result, these enzymes are able to alleviate 
torsional stress (i.e., remove superhelical twists) in duplex DNA.  
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Eukaryotic type I topoisomerases are monomeric enzymes that require no high-energy 
cofactor and are organized into two subclasses: type IA and type IB. These enzymes 
alter topology by creating transient single-stranded breaks in the DNA, followed by 
passage of the opposite intact strand through the break (type IA) or by controlled 
rotation of the helix around the break (type IB).
12
  
Type II topoisomerases act by generating a transient double-stranded DNA break, 
followed by a double stranded DNA passage event. Consequently, these enzymes are 
able to remove superhelical twists from DNA and resolve knotted or tangled duplex 
molecules. Type II topoisomerases function in numerous DNA processes and are 
required for recombination, the separation of daughter chromosomes, and proper 
chromosome structure, condensation, and decondensation.
40
 Two isoforms of the type II 
enzyme are known: topoisomerase II and II. Topoisomerase I and II have been 
shown to represent the principal targets of effective antitumor drugs and, hence, have 
deserved investigation to understand the biochemical and pharmacological basis of drug 
action.
54
 Indeed, topoisomerase poisons, such as antitumor drugs, transform these 
essential enzymes into lethal DNA-damaging agents increasing the concentration of 
covalent topoisomerase-cleaved DNA complex. As result of this action, drugs “poison” 
topoisomerases and convert them to potent cellular toxins that generate breaks in the 
genetic materials of treated cells.
11,42 
 
 
1.5.1 TOPOISOMERASE I 
 
The reaction of topoisomerase I with DNA (Figure 1.14) starts with the binding of the 
enzyme to the double-stranded superhelical DNA. After binding, the enzyme makes a 
transient single-stranded break in the double helix, followed by either a single-stranded 
DNA passage event or controlled rotation about the break; religation and dissociation 
take place subsequently. In details, the interaction enzyme-DNA is controlled to a large 
extent by the surface and charge complementarity of the two reacting species. The 
conformational adaptation of the two partners results in the formation of a tight complex 
whereby the active site tyrosine of human topoisomerase I (Y723) is brought into a 
favourable position for attack of the facing DNA strand and subsequent formation of a 
covalent adduct. After the cut, it happens the release of the superhelical tension by a 
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mechanism called controlled rotation.
43
 Once the DNA is partially relaxed, the covalent 
intermediate in religated, leaving intact the Y723 residue ready for restarting the 
catalytic cycle.  
 
  
 
Figure 1.14 The topoisomerization reaction. Schematically, the cyclic process involves binding of 
topoisomerase I to DNA, followed by DNA cutting and then religation. 
 
 
Chemically (Figure 1.15), topoisomerase I makes a nucleophilic attack with the tyrosine 
active site OH group to the ester of phosphate group. The transient covalent binary 
complex involves the attachment of the enzyme on DNA in the direction of 5’-
phosphate, with the release of a free DNA strand containing a 3’-OH group.42 
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Figure 1.15 Chemical representation of the topoisomerization reaction: cleavage and religation. Y723 
refers to the tyrosine involved in the transesterification reaction with the DNA. By convention, the bases 
flanking the top1 cleavage site are referred to as -1 and +1 for the bases at the 3’P and 5’P DNA termini, 
respectively. 
 
Depending on the point of the reaction cycle at which the drugs, will act topoisomerase 
I inhibitor will reduce or increase the extent of DNA cleavage. An important number of 
topoisomerase I inhibitors have been identified, as coralyne,
44
 benzimidoles, CPT 
(campothecin) and its derivatives, indolocarbazoles;
49
 they can be divided into two 
classes: 
 
 topoisomerase I suppressors correspond to compounds which inhibit the 
enzyme but do not stabilize the intermediate DNA-topoisomerase I covalent 
complex. They inhibit the binding of the protein to the DNA cleavage site, 
blocking the catalytic cycle; 
 
 topoisomerase I poisons (CPT i.e.) act after cleavage of DNA by enzyme and 
inhibit the religation. The drug may freeze the enzyme-DNA complex by three 
ways: the enzyme binds to the preformed drug-DNA complex, the drug 
specifically recognized the enzyme-DNA complex or the drug-enzyme 
association interacts with DNA. 
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1.5.2 TOPOISOMERASE II 
 
The reaction of topoisomerase II starts when the enzyme binds two separate segments of 
DNA. Then it creates a double-stranded break in one of the segments, translocates the 
second DNA segment through the cleaved nucleic acid “gate,” rejoins (i.e., ligates) the 
cleaved DNA, releases the translocated segment through a gate in the protein, close the 
protein gate and regains the ability to start a new round of catalysis.
12
 The scissile bonds 
on the two strands of the double helix that are cut by topoisomerase II are staggered and 
are located across the major groove from one another. Thus, the enzyme generates 
cleaved DNA molecules that contain four-base single-stranded ends at their 5’-termini. 
During its cleavage event, topoisomerase II covalently attaches to these newly 
generated 5’-termini. This covalent enzyme-cleaved DNA complex is known as the 
“cleavage complex”. 
Topoisomerase II requires two cofactors in order to carry out its catalytic double-
stranded DNA passage reaction. First, it needs a divalent cation for all steps beyond 
enzyme–DNA binding, Mg2+ ; second, topoisomerase II uses the energy of adenosine 
triphosphate (ATP) to drive the overall DNA strand passage reaction: the protein binds 
two ATP molecules and undergoes a conformational change that causes the passage of 
the intact DNA segment through the cleaved double helix. 
While ATP is not required for either DNA cleavage or ligation, the binding of this 
nucleoside triphosphate triggers the translocation of DNA through the double-stranded 
nucleic acid gate. ATP hydrolysis is necessary for enzyme recycling. 
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Figure 1.16 Schematic catalytic cycle of topoisomerase II and Effects of inhibitors on the catalytic cycle 
of topoisomerase II. The catalytic cycle of the tomoisomerase homodimer has been described previously 
as a series of six individual reaction steps. Step 1, topoisomerase II binds its DNA substrate. Step 2, a 
transient enzyme-linked double-stranded break is formed in the “cleavage” . Step 3, ATP binding induces 
a conformational change in the enzyme that converts topoisomerase II into a “protein clamp” on the 
DNA. Concomitant with this structural reorientation, the “passage” helix is translocated through the break 
in the cleavage helix. Step 4, the enzyme religates the break in the cleavage helix. Step 5, upon ATP 
hydrolysis, the protein clamp opens, allowing Step 6, release of the DNA and the initiation of a new 
round of catalysis. Drugs that inhibit topoisomerase II catalytic function act at different steps of the 
catalytic cycle. 
 
 
Normally, topoisomerase II binds two molecules of ATP. Although ATP hydrolysis is 
not a prerequisite for the strand passage event, it appears that this step proceeds more 
rapidly if it is preceded by hydrolysis of one of the bound ATP molecules (Figure 
1.16).
12,45-47
 As a result of these processes, topoisomerase II can relax under- or 
overwound (negatively or positively supercoiled) DNA molecules and can remove 
knots and tangles from the genome. These events are essential for cell survival: in 
absence of enzyme, cells cannot segregate daughter chromosomes and die as a result of 
a mitotic failure.
48
  
Topoisomerase II inhibitors can also be divided in two classes: 
 
 topoisomerase II poisons (mitoxantrone, amsacrine, etoposide and other 
epipodophyllotoxins) act inducing the permanent formation of the cleavable 
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complex; their action can happen in three ways: the drug can increase the 
levels of enzyme-DNA cleavage complexes by interacting with topoisomerase 
II at the protein-DNA interface in a non-covalent manner; the drugs can act by 
covalently modifying of enzyme or the structure of DNA; 
 
 topoisomerase II catalytic inhibitors (merbarone, aclarubicin), that inhibit the 
enzyme, but they are not able to induce the formation of cleavable complex. 
 
Interesting is also a third class of compounds called “dual or mixed poison” because 
they act toward both type of topoisomerase (Tas 103 or DACA i.e.).
40
 
 
 
1.6 UV RADIATION IN PHOTOTHERAPY AND 
PHOTOCHEMOTHERAPY 
 
Ultraviolet light, characterized by its short wavelength, is able to pass through the 
different layers of the atmosphere and reach earth. Thus, wavelengths of the ultraviolet 
region of the spectrum, imperceptible to the human eye, are an inherent part of our 
everyday life.
49
 The UV region (190-380 nm) used for photobiological studies, can be 
divided into four parts:
50
 the radiations of UV-A region (320-400 nm) are considered 
harmless and responsible for pigmentation. They are biologically effective and causes 
cellular death, mutation, and DNA damage, although the primary chromophores for 
these effects may be non-DNA sensitizers that are chemically matched to the photon 
energy and act as intermediates relaying the absorbed energy to DNA. UV-A 
phototherapy that utilizes long wave UV-A radiation (340-380 nm) has been shown to 
be very effective in the treatment of several inflammatory skin diseases;
51 
the radiations 
of UV-B region (290-320 nm) as cause of sunburn and photocarcinogenicity (cutaneous 
tumours). UV-B therapy is still the most frequently used phototherapeutic modality for 
the treatment of a variety of skin diseases (psoriasis, atopic dermatitis);
52
 UV-C (200-
290 nm) radiation is photobiologically active because of its mutagenic and antimicrobial 
activity.
49
 In this range some important molecules for cell (DNA) functioning absorb. 
About Vacuum UV (10-190 nm), photons in this region are absorbed by water and 
oxygen (transparent indeed in UV regions above 190 nm). Because of this limited 
penetration, V-UV damage to cells is very weak. 
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In a biological system, the UV radiation can start a photochemical reaction of a 
compound such as decomposition, isomerization or rearrangement can occur and 
unstable photoproducts can react with endogenous molecules resulting in a biological 
effect.
49 
UV radiation is toxic, mutagenic (changes the genotype of cells) and 
carcinogenic (probably by induction of specific oncogenes): so,
 
DNA can be a 
chromophore and a target of this radiation. But the DNA can also be chemically 
modified as a result of the absorption of photon energy by a non-DNA chromophore. In 
this type of reaction, the compound itself may not be chemically changed by absorption 
of radiation, but photon energy is passed to another compound (such as DNA) which 
becomes changed in turn. This process is called photosensitization and the chromophore 
is the photosensitizer. Often, molecular oxygen becomes activated in the 
photosensitization process to form reactive species: the interaction of light, 
photosensitizer and oxygen is also known as photodynamic action. A compound that 
absorbs UV-A photons in living cell exposed to UV-A radiation has the potential to be a 
photosensitizer that will absorb photon energy and pass it to DNA, damaging it. 
Generally, the pathway of energy transfer in a photosensitized reaction is:
 
 
       h      A 
PS    PS*    A* + PS    products 
 
where PS is the photosensitiziers, PS* is the excited-photosensitizer, A and A* are the 
substrate and an excited substrate, and h is the photon energy.53 Although the substrate 
(A) that receives the photon energy from excited sensitizer may be DNA itself, the most 
common substrate in the photosensitized reactions of DNA is molecular oxygen.  
Direct reactions of excited photosensitizer with substrates by one electron transfer are 
called Type I reaction, in contrast to the oxygen-mediated Type II reactions.
54
 
The last ones can act by the generation of singlet oxygen (
1
O2) (major Type II 
mechanism) or by formation of superoxide anion radical (O2
-•
) (minor Type II 
mechanism). 
1
O2, hydroxyl radical and Type I photosensitization are the main reactive 
species in the formation of UV-A-induced damage within the cells. Guanine has known 
to be the base that is modified by this processes (easy oxidation).
55
 
Although the photosensitizers provoke this kind of damage, it has been shown that 
certain drugs (such as psoralens) could be useful for treatment of skin disease (such as 
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psoriasis) in combination with UV-A irradiation (PUVA therapy), in which the 
irreversible binding of a photoexcited molecule of psoralen to DNA takes place.
56
  
Phototherapy consists in the use of light at different wavelengths depending on the 
therapeutic effect sought, in the treatment or therapy of some very specific groups of 
pathologies (especially in the treatment of skin disease). In classic phototherapy, the 
devices used are in wavelength ranges of UV-B (290-315 nm) and UV-A (315-400 nm). 
Photochemotherapy combines the effect of a photosensitizer and of light to achieve 
therapeutic benefits. Without light, the phototerapeutics do not have biological effect 
and the radiation used (visible light or low UV-A doses) is harmless without the drug. 
Only as a result of simultaneous exposure to the phototherapeutic and light, a biological 
effect occurs. So, the properties of light contribute to an high extent to the practical 
specificity of the phototherapy. Two applications of photochemotherapy are in clinical 
use: 
 
 PUVA therapy: the administration of psoralen (P) and UV-A radiation is 
commonly referred as PUVA therapy. Mainly two psoralens are in use for 
PUVA: 5-methoxypsoralen, 8-methoxypsoralen. First applications of PUVA 
were in the treatment of psoriasis and vitiligo, but now it is used for an 
important variety of skin disease. A new development of PUVA is an 
extracorporeal form of photochemotherapy called photopheresis.
57-59
 
 
 Photodynamic therapy: it is based on the use of porphyrins and other 
tetrapyrroles in combination with visible light for treatment of abnormal 
proliferating tissues and it is selective. This therapeutic modality requires the 
presence of oxygen: a porphyrin excited by visible light transfer its excess of 
energy oxygen resulting in the formation of singlet oxygen which is damaging to 
biological system.
60
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2. AIM OF THE PROJECT 
 
Condensed poly(hetero)aromatic compounds are usually regarded as representative 
DNA intercalators, especially if they contain electron-deficient or charged aromatic 
cores in the structure. However, only a few of these compounds interact with nucleic 
acids exclusively by intercalation. A vast number of ligands, which have an 
intercalating part endowed with a variety of substituents, binds to the DNA by a mixed 
mode, since the substituents may also occupy the DNA grooves upon binding and thus 
determine the selectivity and binding of the ligand. Thus, in the case of the “classical” 
intercalator ethidium bromide, the phenyl ring occupies the minor groove, resulting in 
overall heterogeneous DNA binding. At the same time, small changes in the structure of 
a given ligand may lead to the inversion of the binding mode or complete suppression of 
DNA binding, which has been shown for the ethidium derivatives, 9-substituited 
acridizinium salts and diazoniapolycyclic ions.
61 
The consequences of DNA intercalation by exogenous molecules have attracted 
considerable interest in medicinal chemistry, because such a complex formation leads to 
a significant modification of the DNA structure and may result in a hindered or 
supressed function of the nucleic acid in physiological processes (Figure 2.1). 
 
 
 
 
Figure 2.1. Effect of a DNA intercalator agent on DNA structure. 
 
Because such an influence on the biological system is a main requirement for DNA-
targeting drugs, the intercalation of small molecules into DNA may be applied in 
therapeuthic approaches in which the suppression of DNA replication and gene 
transcription is used to destroy tumor cells or infected tissue. As a result, many studies 
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have been performed to gain more insight in different aspects of the association process 
of large and small molecules with DNA in order to obtain highly selective and efficient 
intercalators.
62
 Furthermore, DNA intercalators that inhibit topoisomerase activity or 
that form stabilized ternary complexes with DNA and topoisomerase have high 
potential as DNA-targeting anticancer drugs.
63
 
While the association of cationic dyes to DNA is a reversible process, the DNA 
damage, which frequently occurs on irradiation of ligand-DNA complexes, is often 
irreversible. The latter DNA damage may lead to cell death or mutation, and must be 
avoided in healthy systems. However, this photoinduced DNA-damage may be applied 
in photochemotherapy to remove unwanted cells.
31 
Heterocyclic polyaromatic cations with a quaternary nitrogen atom represent attractive 
and interesting models for the design of water-soluble materials.
 
In particular, the 
quinolizinium derivatives, i.e. arenes containing quaternary bridgehead nitrogen atoms, 
have been shown to bind to DNA and may be employed as a central unit in DNA-
targeting drugs.
64
 
During the studies of the influence of the substitution pattern of quinolizinum 
derivatives on their intercalation with DNA, it has been shown that the tricyclic 
benzo[b]quinolizinium 1 and above all the tetracyclic naphtho[1,2-b]quinolizinium 
bromide 2 (Figure 2.2) have interesting properties with respect to the binding to nucleic 
acids. In particular, the last intercalators may exhibit a stronger interaction with nucleic 
acids as compared with the tricyclic benzo[b]quinolizinium 1 (Figure 2.2) due to the 
additional benzene moiety which extends the surface of the planar chromophore and 
increases the  stacking between the dye and the DNA bases resulting in higher binding 
constants. Other important aspects are represented by the photobiological properties: it 
was shown that an efficient DNA-strand cleavage is photoinduced by the naphtho[1,2-
b]quinolizinium.
31
 Furthermore, the studies in progress on evaluation of the introduction 
of an aryl-substituent in pos. 9 of benzotriciclic structure seems to improve biological 
activity and DNA binding properties. 
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Figure 2.2 Chemical structures of Benzo[b]quinolizinium bromide 1 and Naphtho[1,2-b]quinolizinium 
bromide 2. 
 
The first aim of the project was the synthesis of 3-substituted-naphtho[1,2-
b]quinolizinium derivatives 9; the investigation of these compounds allows to evaluate 
the effects of the extension of  system by the introduction of fourth aromatic ring and 
of the substituent in position 3 (similar structurally to one in pos.9 of benzotriciclic 1) in 
the interaction with DNA. I performed the synthesis in the laboratory of Prof. Heiko 
Ihmels at the Department of Organic Chemistry II (University of Siegen, Germany). 
The strategy was to find a promising general starting material, represented by 3-bromo-
naphtho[1,2-b]quinolizinium bromide 8, that allowed the synthesis of a series of 
corresponding 3-substituted-naphtho[1,2-b]quinolizinium derivatives 9 (Scheme 2.1).  
 
 
N
+
Br
Br
N
+
R
Br  
8              9 
 
Scheme 2.1 Schematic representation of synthetic strategy. 
 
In many cases, the electrophilic aromatic substitution of cationic heteroarenes is an 
inefficient and rather unselective reaction and sometimes the substrates are not 
persistent under the reaction conditions. On the other hand, nucleophilic substitution 
reactions occasionally give the desired products, but in other cases nucleophilic reagents 
induce ring-opening reactions that lead to the destruction of the substrate.
64
 Thus, an 
interesting strategy for the synthesis of 3-aryl-substituted-naphtho[1,2-b]quinolizinium 
derivatives 9 was represented by the Suzuki-Miyaura cross-coupling reaction. This 
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reaction has been shown already to take place between bromo-substituted heterocyclic 
organic cations (such as 9-bromoacridizinium bromide) and arene boronic acids, with 
yields around 40%.
65 
 By this reaction, 3-aryl-substituted-naphtho[1,2-b]quinolizinium 
derivatives were obtained. When the synthesis was completed, the next step was the 
study about DNA-binding properties; then biological studies (cytotoxicity, experiments 
to investigate molecular targets in a preliminary way and to attempt a structure-
relactionship activity) and finally photobiological tests were carried out. 
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3.1 MATERIALS 
 
3.1.1 COMPOUNDS 
 
All the compounds used in this project were synthesized in the laboratory of Prof. Heiko 
Ihmels, Department of Organic Chemistry II, University of Siegen, Germany 
(compounds 9a-9k were synthesized from starting material in according to scheme 3.1; 
compound 2 was synthesized for previously studies and so already available for this 
project): 
 
 9a = FC01: 3-Phenylnaphtho[1,2-b]quinolizinium chloride 
 9b = FC03: 3-(p-Methoxyphenyl)naphtho[1,2-b]quinolizinium bromide 
 9c = FC04: 3-(p-Fluoro)naphtho[1,2-b]quinolizinium bromide 
 9d = FC05: 3-(p-Methylthiophenyl)naphtho[1,2-b]quinolizinium chloride 
 9e = FC06: 3-(3-Thienyl)naphtho[1,2-b]quinolizinium bromide 
 9f = FC07: 3-(4-Pyridyl)naphtho[1,2-b]quinolizinium chloride 
 9g = FC08: 3-[4-(N,N-dimethylaminophenyl)]naphtho[1,2-b]quinolizinium 
chloride 
 9h = FC09: 3-(2-naphthalenyl)naphtho[1,2-b]quinolizinium bromide 
 9i = FC10: 3-(3,4,5-trimethoxyphenyl)naphtho[1,2-b]quinolizinium bromide 
 9j = FC11: 3-(6-methoxy-2-naphthalenyl)naphtho[1,2-b]quinolizinium bromide 
 9k = FC12: 3-(5-pyrimidyl)naphtho[1,2-b]quinolizinium chloride 
 2 = NQZ: naphtho[1,2-b]quinolizinium bromide 
 
3.1.2  REAGENTS AND SOLVENTS 
 
  Al2O3 Neutral, Al2O3 sheets were from Macherey-Nagel, Germany 
 THF, n-Hexane, EtOAc, CH2Cl2, toluene, DMSO, Et2O, MeOH, DME, Acetone, 
CHCl3, DIBAL-H 1.0 M in Hexane, Methyl 6-bromo-2-naphthoate, PBr3, 2-
pyridine carboxaldehyde, ethylene glycol, p-toluene sulfonic acid, KF, 3-
thiophene boronic acid were from Acros Organics, Belgium 
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 NaCl, MgSO4, NaHCO3, Na2SO4, Na2CO3, HBr 48% wt solution in water was 
from Sigma-Aldrich, Munich, Germany 
 Phenyl boronic acid, 4-methoxyphenyl boronic acid, 4-methylthiophenyl boronic 
acid,  Pd(dppf)Cl2-CH2Cl2 ([1,1’-Bis(diphenylphosphino)ferrocene] palladium (II) 
chloride, complex with dichloromethane (1:1), Pd 13 %), 6-methoxy-2-
naphthaleneboronic acid,  3,4,5-trimethoxyphenylboronic acid, 2-
naphthaleneboronic acid were from Alfa Aesar, Karlsruhe, Germany 
 4-fluorophenyl boronic acid and 4-pyridine boronic acid were from Fluorochem, 
UK 
 4-(N,N-dimethylamino)phenyl boronic acid was synthesized for previously studies 
and already available for this project 
 5-pyrimidylboronic acid was from Maybridge, UK 
 Isopropanol and HCl were from Carlo Erba, Italy 
 FBS (fetal bovine serum) was from Invitrogen S.R.L., Milano, Italy 
 Plasmid pBR322 was from Fermentas, Milano, Italy 
 Topoisomerase I was from Calbiochem, Italy 
 Ethidium bromide, agarose, TRIS (tris(hydroxymethyl)aminomethane), EDTA, 
DTT (dithiothreitol, bromophenole blue, trypan blue (), xylene cianol FF, SDS 
(sodium dodecyl solfate), proteinase K, BSA (bovine serum albumin), stDNA 
(sodium salt from salmon testes DNA), MTT [(3-(4,5-dimethylthiazol2yl)2-5 
diphenyl tetrazolium bromide)], HBSS (Hank’s Balanced Salt Solution), Trypsin, 
RPMI-1640 medium, DMEM (Dulbecco’s Modified Eagle’s Medium), penicillin-
streptomycin solutions, Topoisomerase II were purchased from Sigma-Aldrich, 
Milano, Italy.  
 
3.2 METHODS 
 
3.2.1 SYNTHESIS OF COMPOUNDS 
 
All commercially chemicals were reagent grade and used without further purification. 
Melting points were determined with a melting point apparatus (Buchi 510K) and are 
not corrected. NMR spectra were measured on a Bruker Avance 400 (
1
H: 400 MHz, 
13
C: 100 MHz) and chemical shift are given in ppm () relative to TMS ( = 0.00 ppm). 
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Unambiguous proton NMR assignments were established with the help of {1H, 1H} 
COSY, HMBC and HSQC experiments. TLC analyses were performed on silica gel 
sheets (Macherey-Nagel Polygram sil G/UV254; eluent: n-Hexane/EtOAc 1:1) or on 
Al2O3 sheets (Macherey-Nagel Polygram Alox/UV 254; eluent: Chloroform/MeOH 
95:5 or 9:1). Elemental analyses were performed on a KEKA-tech EuroEA combustion 
analyzer by Mr. H. Bodenstedt, Organic Chemistry I, University of Siegen.  
 
3.2.1.1  Synthesis of (6-Bromo-naphthalen-2-yl)-methanol  (6a) 
 
A solution of DIBAL-H (1.0 M in Hexane, 39 g, 55 mL, 55 mmol) was slowly added 
into a solution of methyl 6-bromo-2-naphthoate 5 (5.00 g, 18.9 mmol) in anhydrous 
THF (90 mL) such that the internal temperature of the reaction mixture did not exceed 
25 °C. The reaction mixture was stirred at r.t. until 5 was consumed, as monitored by 
TLC. Then, the reaction was stopped by slow addition into a cooled 4 N HCl aqueous 
solution (200 mL) at 25 °C. The resulting mixture was stirred for 2 h and 200 mL of 
EtOAc were added. The organic layer was separated and the aqueous layer was washed 
with EtOAc (3 x 100 mL). The combined organic layers were washed with 4 N HCl 
aqueous solution (100 mL), 5% aqueous NaHCO3 solution (300 mL) and 6% aqueous 
NaCl solution (300 mL), respectively, and dried with MgSO4. After filtration, the 
solvent was removed in vacuo to give the essentially pure product 6a as determined by 
1
H-NMR as white solid (4.30 g, 96%). M.p.: 153-154 °C (Lit.
66
: 152-153 °C). 
1
H-NMR 
(400 MHz, CDCl3):  = 1.80 (broad s, 1 H, O-H), 4.85 (s, 2 H, CH2), 7.50 (dd, J = 8.5, 
1.7 Hz, 1 H, H-3), 7.55 (dd, J = 8.7, 2.0 Hz, 1 H, H-7), 7.70 (d, J = 8.7 Hz, 1 H, H-8), 
7.75 (d, J = 8.5 Hz, 1 H, H-4), 7.79 (s, 1 H, H-1), 8.00 (d, J = 1.9, 1 H, H-5). 
13
C-NMR 
(100 MHz, CDCl3): = 66.1 (CH2), 120.6 (Cq), 126.1 (CHAr), 127.0 (CHAr), 128.2 
(CHAr), 130.3 (CHAr), 130.4 (CHAr), 130.6 (CHAr), 133.7 (Cq), 134.8 (Cq), 139.6 (Cq). 
 
3.2.1.2  Synthesis of 2-bromo-6-bromomethyl-naphthalene (6b) 
 
To a solution of compound 6a (1.00 g, 4.20 mmol) in anhydrous CH2Cl2 (70 mL), PBr3 
(0.43 mL, d = 2.85 g/mL, 1.22 g, 4.50 mmol) was added at 10 °C and the mixture was 
stirred at r.t. for 3 h. Then, 60 mL of CH2Cl2 were added and the resulting mixture was 
extracted with water (80 mL). The aqueous layer was extracted with CH2Cl2 (3 x 50 
mL). The combined organic layers were washed with an aqueous saturated solution of 
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NaHCO3 (100 mL) and brine (200 mL). The separated organic layer was dried with 
Na2SO4. After filtration, the solvent was removed in vacuo to give the product 6b as 
white-light yellow solid (0.80 g, 65 %), pure as determined by 
1
H-NMR analysis. M.p.: 
128-129 °C (Lit.
67
: 124-125 °C). 
1
H-NMR (400 MHz, CDCl3): = 4.64 (s, 2 H, CH2), 
7.53 (dd, J = 8.5, 1.8 Hz, 1 H, H-7), 7.57 (dd, J = 8.7, 1.9 Hz, 1 H, H-3), 7.68 (d, J = 8.7 
Hz, 1 H, H-4), 7.74 (d, J = 8.5 Hz, 1 H, H-8), 7.80 (s, 1 H, H-5), 7.99 (d, J = 1.7, 1 H, 
H-1). 
13
C-NMR (100 MHz, CDCl3): = 33.8 (CH2), 120.7 (Cq), 127.8 (CHAr), 127.9 (2 
CHAr), 129.6 (CHAr), 129.9 (CHAr), 130.0 (CHAr), 131.7 (Cq), 134.1 (Cq), 135.7 (Cq). 
 
3.2.1.3  Synthesis of 2-(1,3-dioxolan-2-yl)pyridine (7a) 
 
A solution of 2-pyridine carboxaldehyde (42.8 g, 400 mmol), ethylene glycol (45.0 mL, 
800 mmol) and p-toluene sulfonic acid (22.8 g) in toluene (600 mL) was stirred at 
reflux for 36 h in a flask equipped with a modified Dean-Stark apparatus. The reaction 
mixture was cooled to r. t. and poured into an aqueous solution of sodium carbonate 
(2.12 M in water) and the layers were separated. The aqueous layer was extracted with 
toluene (3 x 200 mL). The combined organic layers were washed with water (300 mL) 
and brine (200 mL) and dried with MgSO4. After filtration, toluene was removed in 
vacuo to give the crude product 7a (35 g, 58 %) as a brown liquid, which was purified 
by distillation under vacuum (70 °C, 1.2 mbar), to give a light-yellow liquid. 
1
H-NMR 
(400 MHz, CDCl3): = 4.05-4.22 (m, 4 H, CH2), 5.87 (s, 1 H, CH), 7.26-7.31 (m, 1 H, 
CHAr), 7.54 (d, J = 8.0 Hz, 1 H, CHAr), 7.74 (td, J = 8.0, 2.0 Hz, 1 H, CHAr), 8.63 (m, 1 
H, CHAr). 
  
3.2.1.4  Synthesis of 2-(1,3-dioxolan-2-yl)-6-[2-bromo-
naphthylmethyl] pyridinium bromide (7b) 
 
A solution of 2-(1,3-dioxolan-2-yl)pyridine 7a (1.23 g, 8.10 mmol) and compound 6b 
(2.43 g 8.10 mmol) in DMSO (60 mL) was stirred under an argon gas atmosphere at r.t. 
for 7 days. The reaction mixture was poured into EtOAc (1 L) and the white precipitate 
was collected, washed thoroughly with EtOAc and Et2O and dried under vacuum to 
give the product 7b (2.85 g, 77.9 %), which was used for the following step without 
further purification. M.p.: 197-198 °C. 
1
H-NMR (400 MHz, DMSO-d6): = 4.13 (m, 4 
H, CH2), 6.16 (s, 2 H, CH2), 6.56 (s, 1 H, CH), 7.55 (dd, J = 8.6, 1.8 Hz, 1 H, H-7), 7.70 
(dd, J = 8.8, 2.0 Hz, 1 H, H-3), 7.87 (s, 1 H, H-5), 7.91 (d, J = 8.6, 1 H, H-4), 8.00 (d, J 
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= 8.8 Hz, 1 H, H-8), 8.22 (m, 1 H, H-5’), 8.27 (d, J = 1.8 Hz, 1 H, H-1), 8.36 (dd, J = 
8.0, 1.4 Hz, 1 H, H-3’), 8.75 (m, 1 H, H-4’), 9.1 (dd, J = 6.2, 1.0 Hz, 1 H, H-6’). 13C-
NMR (100 MHz, DMSO-d6): = 60.0 (CH2), 65.6 (CH2), 97.1 (CH), 120.1 (Cq), 126.1 
(Cq), 126.6 (CHAr), 127.5 (CHAr), 128.1 (CHAr), 128.7 (CHAr), 129.6 (CHAr), 129.8 (Cq), 
130.3 (Cq), 131.2 (CHAr), 132.0 (Cq), 133.9 (Cq), 147.3 (CHAr), 147.4 (CHAr), 152.2 
(Cq).  
 
3.2.1.5 Synthesis of 3-bromo-naphtho[1,2-b]quinolizinium bromide 
(8) 
 
A solution of the pyridinium derivative 7b (1.00 g, 2.20 mmol) in aq HBr (48%, 10 mL) 
was stirred under reflux for 4 h. After cooling to r.t., to the formed precipitate were 
added 25 mL of THF and the precipitate was collected, washed with THF and Et2O and 
dried to give the product 8 as orange solid (0.75 g, 88 %). M.p.: 329-330 °C. 
1
H-NMR 
(400 MHz, DMSO-d6): = 8.10 (m, 1 H, H-10), 8.14-8.20 (m, 3 H, H-2, H-5, H-6), 
8.30 (m, 1 H, H-11), 8.50 (d, J = 2.0, 1 H, H-4), 8.64 (d, J = 8.6 Hz, 1 H, H-12), 9.04 (d, 
J = 8.8 Hz, 1 H, H-1), 9.40 (d, J = 8.8 Hz, 1 H, H-9), 10.10 (s, 1 H, H-13), 10.30 (s, 1 H, 
H-7). 
13
C-NMR (100 MHz, DMSO-d6): = 120.8 (CHAr), 123.0 (CHAr), 124.8 (CHAr), 
125.5 (2 Cq), 125.7 (Cq), 127.0 (CHAr), 127.2 (CHAr), 131.3 (CHAr), 131.6 (CHAr), 131.8 
(CAr), 133.4 (CAr), 134.7 (Cq), 134.8 (Cq), 135.0 (CAr), 137.6 (CHAr), 139.0 (Cq). 
 
3.2.1.6 Synthesis of 3-Phenylnaphtho[1,2-b]quinolizinium chloride 
(9a) 
 
Under inert-gas atmosphere a solution of 3-bromo-naphtho[1,2-b]quinolizinium 
bromide 8 (389 mg, 1.00 mmol), phenyl boronic acid (122 mg, 1.00 mmol), 
Pd(dppf)Cl2-CH2Cl2 (24.5 mg, 0.03 mmol) and KF (232 mg, 4.00 mmol) in 
DME/MeOH/H2O (12 mL; 2:1:1) was stirred under reflux for 18 h. After cooling to 
room temperature, MeOH (20 mL) was added to the reaction mixture and the yellow 
precipitate was collected and washed with EtOAc and Et2O. The solid was dissolved in 
hot MeOH and the solution was filtered under vacuum. The desired compound was 
isolated by column chromatography (Al2O3, Activity I; CHCl3-MeOH, 95:5). 
Recrystallization from MeOH gave a pure product 9a (96 mg; 25 %), as dark yellow 
needles. 
1
H-NMR (400 MHz, DMSO-d6): = 7.50 (m, 1 H, H-4’), 7.59 (m, 2 H, H-3’, 
H-5’), 7.96 (m, 2 H, H-2’, H-6’), 8.05 (m, 1 H, H-10), 8.14 (d, J = 9.2 Hz, 1 H, H-5), 
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8.23 – 8.29 (m, 2 H, H-6, H-11), 8.31 (dd, J = 8.6 Hz, 1.9 Hz, 1 H, H-2), 8.53 (d, J = 
1.9 Hz, 1 H, H-4), 8.65 (d, J = 8.4 Hz, 1 H, H-12), 9.17 (d, J = 8.7 Hz, H-1), 9.39 (d, J = 
6.8 Hz, H-9), 10.10 (s, 1 H, H-13), 10.30 (s, 1 H, H-7) . 
13
C-NMR (100 MHz, DMSO-
d6): = 120.5 (CHAr), 122.7 (CHAr), 123.7 (CHAr), 125.8 (CHAr), 125.9 (2 Cq), 126.9 
(CHAr), 127.0 (CHAr), 127.3 (CHAr), 127.5 (CHAr), 128.7 (CHAr), 129.2 (CHAr), 132.8 
(CHAr), 133.0 (CHAr), 134.1 (Cq), 134.8 (CHAr), 135.2 (Cq), 137.5 (CHAr), 138.5 (Cq), 
138.9 (Cq), 143.0 (Cq). M.p.: 345 °C (dec.). Anal. Calcd for C23H16ClN-0.33H2O: C, 
79.42; H, 4.83; N, 4.03. Found: C, 79.57; H, 4.97; N, 4.23. 
 
3.2.1.7 Synthesis of 3-(p-Methoxyphenyl)naphtho[1,2-
b]quinolizinium bromide (9b) 
 
Under inert-gas atmosphere a solution of 3-bromo-naphtho[1,2-b]quinolizinium 
bromide 8 (389 mg, 1.00 mmol), 4-methoxyphenyl boronic acid (304 mg, 2.00 mmol), 
Pd(dppf)Cl2-CH2Cl2 (24.5 mg, 0.03 mmol) and KF (232 mg, 4.00 mmol) in 
DME/MeOH/H2O (12 mL; 2:1:1) was stirred under reflux for 18 h. After cooling to 
room temperature, MeOH (20 mL) was added to the reaction mixture and the yellow 
precipitate was collected and washed with EtOAc and Et2O. This precipitate was 
suspended in acetone (in water-sonic bath for 15 minutes) and the dark yellow solid was 
collected. Recrystallization from MeOH gave a pure product 9b, as red-yellow solid (21 
mg, 5 %), as 
1
H-NMR analysis shows. 
1
H-NMR (400 MHz, DMSO-d6): = 3.86 (s, 3H, 
-OCH3), 7.14 (d, J = 8.7 Hz, 2 H, H-3’, H-5’), 7.94 (d, J = 8.7 Hz, 2 H, H-2’, H-6’), 
8.04 (m, 1 H, H-10), 8.12 (d, J = 9.2, 1 H, H-5), 8.22 – 8.27 (m, 2 H, H-6, H-11), 8.31 
(dd, J = 8.6, 1.8 Hz, 1 H, H-2), 8.49 (d, J = 1.8 Hz, 1 H, H-4), 8.62 (d, J = 8.7 Hz, 1 H, 
H-12), 9.13 (d, J = 8.6 Hz, 1 H, H-1), 9.35 (d, J = 7.0, 1 H, H-9), 10.05 (s, 1 H, H-13), 
10.24 (s, 1 H, H-7) . 
13
C-NMR (100 MHz, DMSO-d6): = 55.3 (-OCH3), 114.7 (CHAr), 
120.2 (CHAr), 122.6 (CHAr), 123.7 (CHAr), 125.2 (Cq) 125.7 (CHAr), 125.8 (Cq), 126.1 
(CHAr), 126.9 (CHAr), 127.0 (CHAr), 128.5 (CAr), 130.6 (Cq), 132.9 (2 CHAr), 134.2 (Cq), 
134.7 (CHAr), 135.3 (Cq), 137.4 (CHAr), 138.9 (Cq), 142.7 (Cq), 159.9 (Cq). M.p.: 335-
336 °C (dec.). Anal. Calcd for C24H18BrNO-0.5H2O: C, 67.74; H, 4.45; N, 3.40. Found: 
C, 67.77; H, 4.50; N, 3.29. 
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3.2.1.8 Synthesis of 3-(p-Fluorophenyl)naphtho[1,2-b]quinolizinium 
chloride (9c) 
 
Under inert-gas atmosphere a solution of 3-bromo-naphtho[1,2-b]quinolizinium 
bromide 8 (389 mg, 1.00 mmol), 4-fluorophenyl boronic acid (280 mg, 2.00 mmol), 
Pd(dppf)Cl2-CH2Cl2 (24.5 mg, 0.03 mmol) and KF (232 mg, 4.00 mmol) in 
DME/MeOH/H2O (12 mL; 2:1:1) was stirred under reflux for 18 h. After cooling to 
room temperature, the palladium-black was removed by filtration and the resulting 
solution was evaporated. EtOAc was added to the residue and the suspension was put in 
sonic bath for 30 minutes. The yellow solid was collected, washed with EtOAc and 
Et2O. The desired compound was isolated by column chromatography (Al2O3, Activity 
I; CHCl3-MeOH, 95:5). Recrystallization from MeOH, gave a pure product 9c (42 mg; 
10 %), as yellow needles.
1
H-NMR (400 MHz, DMSO-d6):  = 7.44 (m, 2 H, H-3’, H-
5’), 8.01-8.06 (m, 3 H, H-2’, H-6’, H-10), 8.15 (d, J = 9.2 Hz, 1 H, H-5), 8.26 (m, 2 H, 
H-6, H-11), 8.31 (dd, J = 8.6, 1.9 Hz, 1 H, H-2), 8.52 (d, J = 1.9 Hz, 1 H, H-4), 8.63 (d, 
J = 8.6 Hz, 1 H, H-12), 9.17 (d, J = 8.6 Hz,1 H, H-1), 9.39 (d, J = 6.9 Hz, 1 H, H-9), 
10.09 (s, 1 H, H-13), 10.28 (s, 1 H, H-7) . 
13
C-NMR (100 MHz, DMSO-d6):  = 116.1 
(2 CHAr J = 21 Hz ), 120.5 (CHAr), 122.7 (CHAr), 123.9 (CHAr), 125.8 (2 Cq), 126.0 
(CHAr), 126.9 (CHAr), 127.0 (CHAr), 127.4 (CHAr), 129.5 (2 CHAr J = 8 Hz), 132.8 
(CHAr), 133.1 (CHAr), 134.1 (Cq), 134.8 (CHAr), 135.0 (Cq J = 3 Hz), 135.2 (Cq), 137.5 
(CHAr), 139.0 (Cq), 142.0 (Cq), 162.3 (Cq J = 244 Hz). M.p.: 352 °C (dec.) Anal. Calcd 
for C23H15ClFN-2H2O: C, 69.78; H, 4.84; N, 3.54. Found: C, 70.16; H, 4.30; N, 3.56. 
 
3.2.1.9 Synthesis of 3-(p-Methylthiophenyl)naphtho[1,2-b] 
quinolizinium bromide (9d) 
 
Under inert-gas atmosphere a solution of 3-bromo-naphtho[1,2-b]quinolizinium 
bromide 8 (389 mg, 1.00 mmol), 4-methylthiophenyl boronic acid (202 mg, 1.20 
mmol), Pd(dppf)Cl2-CH2Cl2 (24.5 mg, 0.03 mmol) and KF (232 mg, 4.00 mmol) in 
DME/MeOH/H2O (12 mL; 2:1:1) was stirred under reflux for 18 h. After cooling to 
room temperature, MeOH (20 mL) was added to the reaction mixture and the yellow 
precipitate was collected and washed with EtOAc and Et2O. The solid was suspended in 
acetone (in water-sonic bath for 15 minutes) and the product 9d, as dark-yellow solid, 
was collected (52 mg, 12 %), pure, as 
1
H-NMR analysis shows. M.p.: °C. 
1
H-NMR (400 
MHz, DMSO-d6): = 2.58 (s, 3H, -SCH3), 7.46 (d, J = 8.4 Hz, 2 H, H-3’, H-5’), 7.94 
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(d, J = 8.4 Hz, 2 H, H-2’, H-6’), 8.05 (m, 1 H, H-10), 8.15 (d, J = 8.9, 1 H, H-5), 8.24 – 
8.28 (m, 2 H, H-6, H-11), 8.33 (dd, J = 7.0, 1.3 Hz, 1 H, H-2), 8.54 (d, J = 1.3 Hz, 1 H, 
H-4), 8.64 (d, J = 8.9 Hz, 1 H, H-12), 9.15 (d, J = 8.6 Hz, 1 H, H-1), 9.37 (d, J = 7.0, 1 
H, H-9), 10.07 (s, 1 H, H-13), 10.26 (s, 1 H, H-7) . 
13
C-NMR (100 MHz, DMSO-d6): 
= 14.4 (-SCH3), 120.4 (CHAr), 122.6 (CHAr), 123.8 (CHAr), 125.7 (2 Cq), 126.1 
(CHAr), 126.3 (CHAr), 126.5 (CHAr), 126.9 (CHAr), 127.1 (CHAr), 127.6 (CHAr), 132.8 
(CHAr), 133.0 (CHAr), 134.2 (CHAr), 134.6 (Cq), 134.8 (Cq), 135.2 (Cq), 137.4 (CHAr), 
139.0 (Cq), 139.4 (Cq), 142.4 (Cq). M.p.: 355-358 °C (dec.). Anal. Calcd for 
C24H18BrNS-0.33H2O: C, 65.75; H, 4.29; N, 3.20; S, 7.31. Found: C, 66.03; H, 4.05; N, 
3.42; S, 7.59. 
 
3.2.1.10 Synthesis of 3-(3-Thienyl)naphtho[1,2-b]quinolizinium 
bromide (9e) 
 
Under inert-gas atmosphere a solution of 3-bromo-naphtho[1,2-b]quinolizinium 
bromide 8 (389 mg, 1.00 mmol), 3-thiophene boronic acid (141 mg, 1.10 mmol), 
Pd(dppf)Cl2-CH2Cl2 (24.5 mg, 0.03 mmol) and KF (232 mg, 4.00 mmol) in 
DME/MeOH/H2O (12 mL; 2:1:1) was stirred under reflux for 18 h. After cooling to 
room temperature, MeOH (20 mL) was added to the reaction mixture and the yellow 
precipitate was collected and washed with EtOAc and Et2O. Recrystallization from 
MeOH gave a pure product 9e, as yellow solid (89 mg, 23 %), as 
1
H-NMR analysis 
shows. M.p.: °C. 
1
H-NMR (400 MHz, DMSO-d6): = 7.77 (m, 1 H, H-4’), 7.84 (m, 1 
H, H-5’), 8.01 (m, 1 H, H-10), 8.09 (m, 1 H, H-5), 8.18 – 8.24 (m, 2 H, H-6, H-11), 8.27 
(s, 1 H, H-2’), 8.33 (m, 1 H, H-2), 8.53 (m, 1 H, H-4), 8.60 (d, J = 8.7 Hz, 1 H, H-12), 
9.07-9.11 (m, 1 H, H-1), 9.33 (d, J = 6.8, H-9), 10.02 (d, J = 2.3, 1 H, H-13), 10.23 (s, 1 
H, H-7) . 
13
C-NMR (100 MHz, DMSO-d6): = 120.3 (CHAr), 122.6 (CHAr), 123.8 (2 
CHAr), 125.5 (Cq), 125.7 (Cq), 125.9 (CHAr), 126.1 (CHAr), 126.3 (CHAr), 126.9 (CHAr), 
127.0 (CHAr), 127.9 (CHAr), 132.7 (CHAr), 133.0 (CHAr), 134.3 (Cq), 134.7 (CAr), 135.2 
(Cq), 137.4 (CHAr), 138.0 (Cq), 139.0 (Cq), 140.0 (Cq). M.p.: 352 °C (dec.). .). Anal. 
Calcd for C21H14BrNS: C, 64.29; H, 3.60; N, 3.57; S, 8.17. Found: C, 64.06; H, 3.41; N, 
3.78; S, 8.47. 
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3.2.1.11 Synthesis of 3-(4-Pyridyl)naphtho[1,2-b]quinolizinium 
chloride (9f) 
 
Under inert-gas atmosphere a solution of 3-bromo-naphtho[1,2-b]quinolizinium 
bromide 8 (389 mg, 1.00 mmol), 4-pyridine boronic acid (135 mg, 1.10 mmol), 
Pd(dppf)Cl2-CH2Cl2 (24.5 mg, 0.03 mmol) and KF (232 mg, 4.00 mmol) in 
DME/MeOH/H2O (12 mL; 2:1:1) was stirred under reflux for 18 h. After cooling to 
room temperature, the palladium-black was removed by filtration and the resulting 
solution was evaporated. EtOAc was added to the residue and the suspension was put in 
sonic bath for 30 minutes. The brown solid was collected, washed with EtOAc and 
Et2O. The desired compound was isolated by column chromatography (Al2O3, Activity 
I; CHCl3-MeOH, 95:5). Recrystallization from MeOH-EtOAc, gave a pure product 9f 
(126 mg; 33 %), as brown-orange needles. 
1
H-NMR (400 MHz, DMSO-d6):  = 8.08 
(m, 2 H, H-3’, H-5’), 8.09 (m, 1 H, H-10), 8.18 (d, J = 9.2 Hz, 1 H, H-5), 8.28 (m, 2 H, 
H-6, H-11), 8.44 (dd, J = 8.6, 1.9 Hz, 1 H, H-2), 8.67 (d, J = 8.6, 1 H, H-12), 8.70 (d, J 
= 1.8, 1 H, H-4), 8.77 (m, 2 H, H-2’, H-6’), 9.24 (d, J = 8.6 Hz, 1 H, H-1), 9.41 (d, J = 
6.8, 1 H, H-9), 10.16 (s, 1 H, H-13), 10.32 (s, 1 H, H-7) . 
13
C-NMR (100 MHz, DMSO-
d6):  = 121.0 (CHAr), 121.7 (2 CHAr), 123.0 (CHAr), 124.1 (CHAr), 125.9 (Cq), 126.1 
(CHAr), 127.0 (CHAr), 127.2 (Cq), 127.4 (CHAr), 127.7 (CHAr), 132.6 (CHAr), 133.3 
(CHAr), 134.1 (Cq), 134.9 (CHAr), 135.0 (Cq), 137.6 (CHAr), 139.0 (Cq), 140.0 (Cq), 
145.0 (Cq), 150.5 (2 CHAr). M.p.: 357-360 °C (dec.). Anal. Calcd for C22H15ClN2-HCl-
0.33H2O: C, 68.58; H, 4.36; N, 7.29. Found: C, 68.36; H, 4.66; N, 7.19 
 
3.2.1.12 Synthesis of 3-[4-(N,N-dimethylaminophenyl)]naphtho[1,2-
b]quinolizinium chloride (9g) 
 
Under inert-gas atmosphere a solution of 3-bromo-naphtho[1,2-b]quinolizinium 
bromide 8 (389 mg, 1.00 mmol),  4-(N,N-dimethylamino)phenylboronic acid (182 mg, 
1.10 mmol), Pd(dppf)Cl2-CH2Cl2 (24.5 mg, 0.03 mmol) and KF (232 mg, 4.00 mmol) in 
DME/MeOH/H2O (12 mL; 2:1:1) was stirred under reflux for 18 h. After cooling to 
room temperature, MeOH (10 mL) was added to the reaction mixture, the palladium-
black was removed by filtration and the yellow precipitate was collected and washed 
with EtOAc and Et2O. The desired compound was isolated by column chromatography 
(Al2O3, Activity I; CHCl3-MeOH, 95:5). Recrystallization from MeOH gave a pure 
product 9g (132 mg; 31 %), as dark red powder. 
1
H-NMR (400 MHz, DMSO-d6): = 
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3.02 (s, 6 H, 2 -NCH3), 6.87 (d, J = 8.8 Hz, 2 H, H-3’, H-5’), 7.83 (d, J = 8.8 Hz, 2 H, 
H-2’, H-6’), 8.00 (m, 1 H, H-10), 8.08 (d, J = 9.2 Hz, 1 H, H-5), 8.20 – 8.25 (m, 3 H, H-
2, H-6, H-11), 8.40 (d, J = 1.5 Hz, 1 H, H-4), 8.60 (d, J = 8.5 Hz, 1 H, H-12), 9.04 (d, J 
= 9.0 Hz, 1 H, H-1), 9.33 (d, J = 7.0 Hz, 1 H, H-9), 9.97 (s, 1 H, H-13), 10.23 (s, 1 H, 
H-7); 
13
C-NMR (100 MHz, DMSO-d6): = 40.8 (2 -NCH3), 112.9 (2 CHAr),  120.2 
(CHAr), 122.8 (CHAr), 123.8 (CHAr), 124.8 (Cq), 125.2 (CHAr), 125.5 (Cq), 125.9 (Cq), 
126.1 (CHAr), 126.6 (CHAr), 127.2 (CHAr), 128.2 (2 CHAr), 133.1 (CHAr), 133.4 (CHAr), 
134.7 (Cq), 135.0 (CHAr), 135.7 (Cq), 137.7 (CHAr), 139.2 (Cq), 143.6 (Cq), 151.0 (Cq); 
m.p.: 320 °C (dec.). Anal. Calcd for C25H21ClN2-H2O: C, 74.52; H, 5.75; N, 6.90. 
Found: C, 74.09; H, 5.69; N, 7.02. 
 
3.2.1.13 Synthesis of 3-(2-naphthalenyl)naphtho[1,2-b]quinolizinium 
bromide (9h) 
 
Under inert-gas atmosphere a solution of 3-bromo-naphtho[1,2-b]quinolizinium 
bromide 8 (389 mg, 1.00 mmol),  2-naphthaleneboronic acid (230 mg, 1.10 mmol), 
Pd(dppf)Cl2-CH2Cl2 (24.5 mg, 0.03 mmol) and KF (232 mg, 4.00 mmol) in 
DME/MeOH/H2O (12 mL; 2:1:1) was stirred under reflux for 18 h. After cooling to 
room temperature, MeOH (10 mL) was added to the reaction mixture, the palladium-
black was removed by filtration. The yellow precipitate was collected and washed with 
EtOAc and Et2O. Recrystallization from MeOH gave a pure product 9h (214 mg; 49%), 
as dark yellow powder. 
1
H-NMR (400 MHz, DMSO-d6): = 7.60 (m, 2 H, H-6’, H-7’), 
8.00-8.19 (m, 6 H, H-5, H-10, H-3’, H-4’, H-5’, H-8’), 8.25 (m, 1 H, H-11), 8.31 (d, J = 
8.8 Hz, 1 H, H-6), 8.47 (dd, J = 8.6 Hz, 1.8 Hz, 1 H, H-2), 8.54 (s, 1 H, H-1’), 8.65 (d, J 
= 8.5 Hz, 1 H, H-12), 8.68 (d, J = 1.8 Hz 1 H, H-4), 9.20 (d, J = 8.5 Hz, 1 H, H-1), 9.36 
(d, J = 6.7 Hz, 1 H, H-9), 10.09 (s, 1 H, H-13), 10.26 (s, 1 H, H-7); 
13
C-NMR (100 
MHz, DMSO-d6): = 120.9 (CHAr), 123.1 (CHAr), 124.2 (CHAr), 125.4 (CHAr), 126.1 
(Cq), 126.2 (Cq), 126.3 (CHAr), 126.7 (CHAr), 127.1 (CHAr), 127.2(CHAr), 127.3 (CHAr), 
127.6 (CHAr), 127.9 (CHAr), 128.0 (CHAr), 128.8 (CHAr), 129.2 (CHAr), 133.1 (Cq), 
133.2 (Cq) 133.4 (CHAr), 133.6 (CHAr), 134.5 (Cq), 135.1 (Cq), 135.5 (CHAr), 136.1 
(Cq), 137.8 (CHAr), 139.3 (Cq), 143.1 (Cq); m.p.: 365 °C (dec.). .). Anal. Calcd for 
C27H18BrN-0.5H2O: C, 71.37; H, 4.4; N, 3.08. Found: C, 71.35; H, 4.32; N, 3.12. 
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3.2.1.14 Synthesis of 3-(3,4,5-trimethoxyphenyl)naphtho[1,2-b] 
quinolizinium bromide (9i) 
 
Under inert-gas atmosphere a solution of 3-bromo-naphtho[1,2-b]quinolizinium 
bromide 8 (389 mg, 1.00 mmol),  3,4,5-trimethoxyphenylboronic acid (189 mg, 1.10 
mmol), Pd(dppf)Cl2-CH2Cl2 (24.5 mg, 0.03 mmol) and KF (232 mg, 4.00 mmol) in 
DME/MeOH/H2O (12 mL; 2:1:1) was stirred under reflux for 18 h. After cooling to 
room temperature, MeOH (10 mL) was added to the reaction mixture, the palladium-
black was removed by filtration; the solvent was evaporated and the yellow powder was 
collected and washed with EtOAc and Et2O. The desired compound was isolated by 
column chromatography (Al2O3, Activity I; CHCl3-MeOH, 95:5). Recrystallization 
from MeOH-Et2O gave a pure product 9h (21.6 mg; 4.5 %), as yellow powder. 
1
H-
NMR (400 MHz, DMSO-d6): = 3.76 (s, 3 H, -OCH3), 3.96 (s, 6 H, 2 -OCH3), 7.23 (s, 
2 H, H-2’, H-6’), 8.06 (m, 1 H, H-10), 8.16 (d, J = 9.1 Hz, 1 H, H-2), 8.24 – 8.30 (m, 2 
H, H-6, H-11), 8.36 (dd, J = 8.6 Hz, J = 1.9 Hz, 1 H, H-2), 8.56 (d, J = 1.9 Hz, 1 H, H-
4), 8.67 (d, J = 8.8 Hz, 1 H, H-12), 9.16 (d, J = 8.8 Hz, 1 H, H-1), 9.40 (d, J = 6.7 Hz, 1 
H, H-9), 10.10 (s, 1 H, H-13), 10.30 (s, 1 H, H-7); 
13
C-NMR (100 MHz, DMSO-d6): 
= 56.2 (-OCH3), 60.0 (2 -OCH3), 104.8 (2 CHAr), 120.3 (CHAr), 122.6 (CHAr), 123.6 
(CHAr), 125.6 (CHAr), 125.7 (Cq), 126.8 (CHAr), 126.9 (CHAr), 127.6 (CHAr), 132.7 
(CHAr), 132.9 (CHAr), 134.0, (Cq), 134.1 (Cq), 134.8 (Cq), 135.1 (CHAr), 137.4 (Cq), 
138.1 (CHAr), 138.9 (Cq), 143.1 (Cq), 153.3 (3 Cq). m.p.: 295 °C (dec.). Anal. Calcd for 
C26H22BrNO3-2.5H2O: C, 59.89; H, 5.22; N, 2.69. Found: C, 59.82; H, 4.92; N, 2.78. 
 
3.2.1.15 Synthesis of 3-(6-methoxy-2-naphthalenyl)naphtho[1,2-b] 
quinolizinium bromide (9j) 
 
Under inert-gas atmosphere a solution of 3-bromo-naphtho[1,2-b]quinolizinium 
bromide 8 (389 mg, 1.00 mmol),  6-methoxy-2-naphthaleneboronic acid (230 mg, 1.10 
mmol), Pd(dppf)Cl2-CH2Cl2 (24.5 mg, 0.03 mmol) and KF (232 mg, 4.00 mmol) in 
DME/MeOH/H2O (12 mL; 2:1:1) was stirred under reflux for 18 h. After cooling to 
room temperature, MeOH (10 mL) was added to the reaction mixture, the palladium-
black was removed by filtration and the yellow precipitate was collected and washed 
with EtOAc and Et2O. The desired compound was isolated by column chromatography 
(Al2O3, Activity I; CHCl3-MeOH, 9:1). Recrystallization from MeOH-Et2O gave a pure 
product 9h (42 mg; 9 %), as orange-yellow powder. 
1
H-NMR (400 MHz, DMSO-d6): 
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= 3.93 (s, 3 H, -OCH3), 7.25 (dd, J = 9.0 Hz,  1.8 Hz, 1 H, H-7’), 7.41 (s, 1 H, H-5’), 
7.95-8.10 (m, 4 H, H-10, H-3’, H-4’, H-8’), 8.15 (d, J = 9.0 Hz, 1 H, H-6), 8.25 (m, 1 H, 
H-11), 8.30 (d, J = 9.0 Hz, 1 H, H-5), 8.45 (m, 2 H, H-2, H-1’), 8.64 (m, 2 H, H-4, H-
12), 9.18 (d, J = 8.5 Hz, 1 H, H-1), 9.37 (d, J = 7.0 Hz, 1 H, H-9), 10.08 (s, 1 H, H-13), 
10.28 (s, 1 H, H-7); 
13
C-NMR (100 MHz, DMSO-d6): = 55.7 (-OCH3), 106.2 (CHAr), 
119.7 (CHAr), 120.8 (CHAr), 123.0 (CHAr), 124.2 (CHAr), 125.8 (CHAr), 126.0 (Cq), 
126.1 (Cq), 126.3 (CHAr), 126.6 (CHAr), 127.2 (CHAr), 127.3 (CHAr), 127.7 (CHAr), 
128.1 (CHAr), 129.1 (Cq), 130.9 (CHAr), 133.2 (CHAr), 133.3 (CHAr), 133.7 (Cq), 134.6 
(Cq), 134.7 (Cq) 135.1 (CHAr), 135.6 (Cq), 137.8 (Cq), 139.3 (Cq), 143.3 (Cq), 158.3 
(Cq); m.p.: 323 °C (dec.). Anal. Calcd for C28H20BrNO-1.5H2O: C, 68.16; H, 4.70; N, 
2.84. Found: C, 68.36; H, 4.63; N, 3.03. 
 
3.2.1.16 Synthesis of 3-(5-pyrimidyl)naphtho[1,2-b]quinolizinium 
chloride (9k) 
 
Under inert-gas atmosphere a solution of 3-bromo-naphtho[1,2-b]quinolizinium 
bromide 8 (389 mg, 1.00 mmol), 5-pyrimidylboronic acid (136 mg, 1.10 mmol), 
Pd(dppf)Cl2-CH2Cl2 (24.5 mg, 0.03 mmol) and KF (232 mg, 4.00 mmol) in 
DME/MeOH/H2O (12 mL; 2:1:1) was stirred under reflux for 18 h. After cooling to 
room temperature, MeOH (10 mL) was added to the reaction mixture, the palladium-
black was removed by filtration and the brown precipitate was collected and washed 
with EtOAc and Et2O. The desired compound was isolated by column chromatography 
(Al2O3, Activity I; CHCl3-MeOH, 95:5). Recrystallization from MeOH-Et2O gave a 
pure product 9k (37.7 mg; 9.7 %), as brown-yellow powder. 
1
H-NMR (400 MHz, 
DMSO-d6): = 8.10 (m, 1 H, H-10), 8.20 (d, J = 9.3 Hz, 1 H, H-5), 8.27-8.32 (m, 2 H, 
H-6, H-11), 8.50 (dd, J = 8.6 Hz, 1.9 Hz, 1 H, H-2), 8.67 (d, J = 8.6 Hz, 1 H, H-12), 
8.72 (d, J = 1.8 Hz, 1 H, H-4), 9.26 (d, J = 8.6 Hz, H-1), 9.31 (s, 1 H, H-3’), 9.42 (d, J = 
6.6 Hz, 1 H, H-9), 9.46 (s, 2H, H-4’, H-6’), 10.15 (s, 1 H, H-13), 10.28 (s, 1 H, H-7); 
13
C-NMR (100 MHz, DMSO-d6): = 121.3 (CHAr), 123.3 (CHAr), 124.6 (CHAr), 126.2 
(Cq), 126.6 (CHAr), 127.2 (Cq), 127.4 (CHAr), 127.8 (CHAr), 128.0 (CHAr), 132.3 (Cq), 
132.8 (CHAr), 133.7 (CHAr), 134.4 (Cq), 135.3 (Cq), 135.4 (CHAr), 137.1 (Cq), 138.0 
(CHAr), 139.4 (Cq), 155.7 (2 CHAr), 158.4 (CHAr); m.p.: 365 °C (dec.). Anal. Calcd for 
C21H14ClN3-2H2O: C, 67.46; H, 4.67; N, 11.24. Found: C, 67.25; H, 4.51; N, 11.24. 
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3.2.2 SPECTROPHOTOMETRICAND 
SPECTROFLUORIMETRIC TITRATIONS 
 
3.2.2.1 Spectrophotometric titrations 
 
Spectrophotometric titration of 3-aryl-substituted-naphtho[1,2-b]quinolizinium 
derivatives 9 with stDNA were performed in phosphate buffer 10 mM at pH = 7.0 for 
the determination of the interaction between them and DNA.  
The ligand concentration was 10 or 20 M and the titrant solutions contained stDNA 
(4.5 mM (bp)) as well as the ligand at the same concentration as in the titrated solution 
to avoid dilution of the analyte in cuvette. Aliquots (3 ml) of the analyte solutions in 
phosphate buffer were placed into quartz spectrophotometric cells and titrated with the 
titrant solutions in 0.5-2 equivalent intervals. UV-Vis spectra were recorded on a Uv-
Vis Perkin-Elmer Lambda 12 double beam spectrophotometer (wavelength range of 
300-500 nm). The titrations were finished after no changes were observed in absorption 
spectra upon addition of at least three two-equivalent portions of the titrant. All the 
spectrophotometric titrations were performed at least three times to ensure the 
reproducibility. Moreover, to avoid secondary effects (charge-charge interactions), the 
titrations were confirmed using a higher ionic strength buffer (ETN 100 mM). 
 
3.2.2.2 Spectrofluorimetric titrations 
 
Spectrofluorimetric titrations were performed with the same methods of 
spectrophotometric titrations and this technique was chosen for the determination of 
binding constants because its high sensitivity. In this case, a ligand concentration cL = 
0,5 or 1 M was used. The spectra were recorded on a Perkin-Elmer LS50B Fluorimeter 
(wavelength range 400-600 nm). All the spectrofluorimetric titrations were performed at 
least three times to ensure the reproducibility. 
 
3.2.2.3 Evaluation of binding costants (K) and binding site size (n)  
 
The concentration of the drug bound (Cb) to the DNA was calculated by these 
equations: 
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Cf  = CT ×  
 
Cb = CT – Cf 
 
Here Cf is the amount of free drug, CT is the known added amount of drug, I0 is the ratio 
of fluorescence intensity of drug in absence of DNA, I is the ratio of fluorescence 
intensity in presence of DNA and P is the ratio of observed quantum yield of 
fluorescence of the totally bound drug to that of the free drug; the quantity P was 
determined by adding DNA to a known quantity of drug until no further change in 
fluorescence emission was observed. The ratio P = I∞ / I0 was the obtained from the 
initial value of I and the plateau value of I at high DNA concentration.
68
 
After that, the ratio of bound ligand molecules per DNA base pair (r) is: 
 
r =   
 
The data were presented as Scatchard plot,
 
 i.e.,  r/Cf  vs r values, and numerically fitted 
to the neighbour exclusion model of McGhee and von Hippel,
69
 to determine the values 
of the binding constant (K) and the binding site size (n). The numerical fitting was 
performed using non-linear curve fitting algorithm implemented into the Sigma-Plot
®
 
software. 
 
 = K (1 – nr)  
 
 
3.2.3 LINEAR DICHROISM 
 
Linear dichroism is defined as the differential absorption of orthogonal forms of linearly 
polarized light: 
 
LD = A// - A┴ 
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A// corresponds to the absorbance of the sample when the light is polarized parallel to 
the orientation of flow, and A┴ is the perpendicular absorbance. The “reduced” linear 
dichroism, LDr, reflects the dependance of the LD on the wavelength: 
 
LDr =  
 
Aiso is the absorbance of an isotropic sample, determined by the measurement of 
absorption spectra of ligand-DNA complexes. The “reduced” linear dichroism may be 
related to the orientation of DNA (S) and the angle between the respective light-
absorbing transition moment and the DNA helix axis:
70 
 
LDr =  × S (3cos
2 - 1) 
 
Assuming a value of  = 90° for the DNA bases for a ligand bound to it, L is can be 
given: 
 
L = arccos  
 
(LDr)L is the reduced LD for the ligand, (LDr)DNA is the reduced LD for DNA and L 
defines the ligand-DNA relative orientation. In the case of intercalation, L ≈ 90° and 
(LDr)L ≈ (LDr)DNA. The measurements of absoption spectra of ligand-DNA complexes 
were recorded in phosphate buffer in a flow cell on a Jasco J500A spectropolarmeter 
equipped with an IBM PC and a Jasco J interface. Partial alignment of the DNA was 
provided by a linear-flow device at a shear gradient of 800 RPM. 173. Concentration of 
DNA was 0.75 mM (bp) and measurements were performed at [Ligand]/[DNA] = 0, 
0.02, 0.04. 0.08, 0.2. 
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3.2.4 CIRCULAR DICHROISM SPECTROSCOPY 
 
Circular dichroism is defined as the differential absorption of right- (AR) and left-
handed (AL) circularly polarized light. At a given wavelength: 
 
CD() = AR() – AL() 
 
Linearly polarized light is a electromagnetic radiation defined by an electric field 
vector, that oscillates in one plane, similar to a sine wave. In circularly light polarized 
the electric field rotates along the propagation direction, defining a helix in the space, 
moving a track: if this is a left-handed helix, the light is referred to as left circularly 
polarized, conversely for right-handed helix. The electric field of light beam causes a 
linear displacement of charge when interacting with a molecule, whereas the magnetic 
field of it causes a circulation of charge. These two motions combined result in a helical 
displacement when light is impinged on a molecole. So, in a achiral sample, the 
absorbition of light will be the same from right or left with generation of plane polarized 
light. In a chiral sample, there will be a CD signal, due to fact that one of the two types 
of circularly polarized light are absorbed in different extents. Due to the interaction with 
the molecule, the electric field vector of the light traces out an elliptical path while 
propating. The circular dichroism effect is small so the ellipticity values usually ar on 
the order of mdeg;
71,72
 the ellipticity in radians is: 
 
 =  (AL – AR) [rad] 
 
And it could be converted into mdeg: 
 
 =  (AL – AR)  [deg] 
 
Circular dichroism spectra were recorded in 10 mM phosphate buffer solution, pH = 7.0 
in a quartz sample cuvette, (pathlength ℓ = 1 cm) at 20 °C on a Chirascan (Applied 
Photophysics Limited, UK) apparatus. At first, measurements with DNA alone and 
ligand alone (10 M) were performed; the other measurements were performed at 
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[Ligand]/[DNA] = 0, 0.08, 0.2 ratios on a Chirascan (Applied Photophysics Limited, 
UK) apparatus. 
 
3.2.5 IRRADIATION PROCEDURE 
 
HPW 125 Philips lamps, emetting at 365 nm, were used for irradiation experiments. 
The spectral irradiance of the source 4.0 mW cm
-2
 as measured, at the sample level, by 
aCole-Parmer Instrument Company radiometer (Niles, IL), equipped with a 365-CX 
sensor. 
 
3.2.6 DNA PHOTOCLEAVAGE 
 
In order to investigate the DNA photocleavage activity, all the compounds were 
irradiated, under aerobic conditions in phosphate buffer, in the presence of supercoiled 
double stranded pBR322 plasmid, which it is a very sensitive tool for damages 
detection. The irradiation of a photosensitizier could make a damage at single or both 
strands of the plasmid, inducing the formation of different hydrodynamic forms as OC 
(form II: open circular) and L (form III: linear). It is possible to separate the three 
different forms with horizontal electrophoresis because of their different hydrodynamic 
properties. So the reaction mixtures were resolved by agarose electrophoresis and the 
DNA bands were detected and quantified. 
 
3.2.6.1 Determination of strand breaks 
 
The plasmid solution (40 l), containing pBR322 (0.20 g) and the selected compound 
at increasing [Drug]/[DNA] ratios = 0.5, 1, 1.5, was irradiated with different UVA 
doses (En = 0, 3.75 and 7.5 J/cm
2
). After the addition of 4 l of loading buffer (0.25% 
bromophenol blue, 0.25% xylene cianol, 30% glycerol in water), the samples were 
loaded on 1% agarose gel and the run was carried out in TAE buffer (40 mM Tris-
acetate, 1 mM EDTA) at 80 V for 2 hours. After staining with ethidium bromide 
solution (0.5 g/ml), gel was washed with water and the DNA bands were detected with 
a UV transilluminator. Photographs were taken by a digital photocamera Kodak DC256 
and the quanitification of the bands was achieved by image analyzer software Quantity 
one (BIO-RAD, Milano, Italy). The fractions of supercoiled DNA (Form I) were 
calculated by this equation: 
3. Experimental procedures  
54 
 
sc – DNA =  
 
Areasc is the area of supercoiled DNA (form I) and Areacl is the area of the open circular 
or linear DNA (form II and III, espectively) obtained by the densiometric analysis of 
gel. The presence of coefficent 1,66 in the formula is due to fact that ethiudium bromide 
bound to the supercoiled pBR322 is 1,66 times less than that bound to form II and III.
73
 
Each experiment was repeated at least three times. 
 
3.2.7 CELLULAR CYTOTOXICITY AND PHOTOTOXICITY 
 
3.2.7.1 Cell Cultures 
 
Various human tumor cell lines were tested, both leukemic and solid tumor, as: Jurkat 
are human T-lymphoblastic cells; K562 are chronic myelogenous leukemia cells, CEM 
are human T lymphoblastic cells, RS 4;11 are human B-lymphoblastic acute leukemia 
cells, SEM are human B-lymphoblastic acute leukemia cells, MV 4;11 are monocytic 
acute leukemia cells. All leukemic cells were grown in RPMI-1640 medium 
supplemented with 115 units/ml of penicillin G, 115 g/ml streptomycin and 10% heat-
inactivated fetal bovine serum (complete RPMI-1640 medium). Cells were kept at 37° 
C in 5% CO2 humidified atmosphere and re-seeded into fresh medium three times a 
week.  
MCF-7 are human breast carcinoma cells; A549 are human lung carcinoma cells, A431 
are human epidermic carcinoma, HeLa are human cervix carcinoma cells, HT29 are 
colon adenocarcinoma cells. All these cells were grown in DMEM medium 
supplemented with 115 units/ml of penicillin G, 115 g/ml streptomycin and 10% heat-
inactivated fetal bovine serum (complete DMEM medium). Cells were kept at 37° C in 
5% CO2 humidified atmosphere and re-seeded into fresh medium twice a week.  
 
3.2.7.2 Evaluation by MTT test 
 
Individual wells of 96-well tissue culture microtiter plate were inoculated with 100 l of 
complete medium containing 5000 cells. The plates were incubated at 37°C in a 
humidified 5% CO2 incubator for 24 hours prior the cell viability experiments. The 
compounds were dissolved in DMSO, then diluted with appropriate complete medium 
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for cytotoxicity assay. After medium removal, 100l of the drug solution in different 
concentrations were added to each well and incubated at 37°C for 72 hours. 
In the case of photocytotoxicity, the compounds were diluted in Hank’s Balance Salt 
Solution (HBSS pH = 7,2), and cells were incubated with them for 30 minutes at 37°C 
and then irradiated with UVA (En = 2.5 and 3.75 J/cm
2
). Finally, the drug solution was 
replaced with the appropriate complete medium and the plates were incubated for 72 
hours. 
After the period of incubation, in both cases, the cell viability was evaluated by MTT 
[(3-(4,5-dimethylthiazol2yl)2,5 diphenyl tetrazolium bromide)] test.
74
 In each well, 10 
l of MTT, 5 mg/ml in PBS, were added and plates were put into the incubator for 3 
hours. MTT is a yellow dye that can be absorbed by cells and reduced by mitochondrial 
dehydrogenases, producing blue insoluble crystals. After incubation, crystals were 
solubilized adding 100 l of 0.08 N HCl in isopropanol and plates were detected 
through microplate BIO-RAD reader at  = 570 nm. The absorbance of ach sample was 
corrected by instrument which subtracted the mean value of blanks, i.e., well in which 
there is medium except cells. The absorbance is proportional with cellular viability, so 
the cellular survival was calculated by this equation: 
 
% cell survival =   
 
A100% = means of control, i.e., cells without drug or irradiation exposure, which represent 100% of 
survival. 
Asample = absorbance of various samples in which cells were in contact with drug or irradiated in presence 
of drug. 
 
For every cellular line, GI50, i.e., the drug concentration that induce 50% of inhibition of 
growth of treated cells, was calculated by SigmaPlot
® 
software. Each experiment was 
repeated at least three times. 
 
3.2.7.3 Evaluation by trypan blue test 
 
Individual wells of 24-well tissue culture microtiter plate were inoculated with 1 ml of 
complete medium containing 300000 cells. The experiment is based on the counting 
cells at t = 0 h (cells non treated with drugs), at t = 24 h, 48 h and 72 h (cells treated 
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with drug respectively at 24 h, 48 h, 72 h from exposure). After the counting of cells (t 
= 0 h), drug was added in each well to have 2.5 M, 5 M, 10 M concentrations. The 
counting of cells was carried out by microscope after adding 5 l of trypan blue 
((3Z,3'Z)-3,3'-[(3,3'-dimethylbiphenyl-4,4'-diyl)di(1Z)hydrazin-2-yl-1-ylidene] bis(5-
amino-4-oxo-3,4-dihydronaphthalene-2,7-disulfonic acid)) to 25 l of cell suspension.  
 
3.2.8 CONFOCAL MICROSCOPY 
 
The confocal microscope is a technique that provides true three dimensional imaging 
and resolution.  
In a 35 mm Petri dishes, 150.000 HeLa cells were incubated at 37°C in the presence of 
the selected compounds for 1-2 h. Cellular fluorescence images were acquired with an 
video-confocal microscope (NIKON), using a Nir Apo 60X/1.0W water immersion 
objective (NIKON). Emission filter settings were used to separate the emission of the 
probes from that of the test compounds. 
 
3.2.9 FLOW CYTOMETER 
 
Flow cytometry is an useful and important technique to obtain cellular characteristics 
(presence of membrane antigens with immunofluorescence methods, cellular volume, 
granularitym or cellular membrane permeability); also, it makes statistical analysis in 
samples of microscopic dispersed particles in liquid suspension, throught light diffusion 
and fluorescence phenomena. Flow cytometry presents numerous advantages: the 
possibility of multiparametric analysis, reproducibility, high speed of analysis, high 
number of analysed cells and semplicity of preparation of samples. 
The instrument (Figure 3.1) is composed by:  
 
 A fluidic system composed by a flow cell (a special capillary, usually in 
quartz) where an hydrodinamic apparatus allowed to obtain the so-called 
“hydrodinamic focalization”. In this system, single particles are forced to flow 
at the centre of this capillary, where ideally they can perform laminar flow. 
Inside this flow cell, particles are in single line, so the instrument has the 
possibility to take single measures sequentially; 
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 An optical system: the light source can be a laser or a mercury vapour lamp. 
The optical system lets the beam arrives in the capillary core where it is 
focalized to each single cell flowing. Signals from cells are sent to respective 
photomultipliers. There is also an optical system parallel and orthogonal to 
light beam to check side scattering (SS) and forward scattering (FS). The first 
one givs information about cellular morphology (shape, cytoplasmatic 
granularity), while the second one about the size of objects. In the SS there are 
also fluorescent phenomena if fluorochromes are used for analysis (FITC, PE); 
 an electronic system and a mechanic system; 
 a data SW-analysis-system: the emitted light is checked for spectral analysis 
(separation of wavelength by dichroic spectra) and it is sent to a 
photomultiplier to amplify signals that are trasformed to electric impulses and 
digitised. A computer analyses data and lets their visualization.  
 
 
 
Figure 3.1 Schematic representation of a flow cytofluorimeter. 
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3.2.9.1 Analysis of cell cicle 
 
The analysis of cell cycle was conducted through flow cytometry; this test is based in 
the fact that each phase presents a different content of DNA. 
Diagrams of growing cultures display the characteristic x-axis distribution according to 
the DNA content, the first peak corresponding to the diploid peak, i.e., to cells in the G1 
phase, and the second peak to cells with doubled DNA content, i.e., to cells in G2/M 
phase. 
Cells with an intermediate DNA content are in the S phase. When DNA is fragmented, 
as in apoptotic cells, the affinity with the intercalating PI dye is decreased and a so-
called hypodiploid peak is present to the left of the G1 peak (Figure 3.2). 
 
 
 
 
 
Figure 3.2 Schematic representation of cell cycle distribution. 
 
For flow cytometric analysis of DNA content, 5x10
5
 A549 cells were treated with the 
selected compounds for 24 hours at 2.5, 5, 10 M concentrations. After the incubation 
period, cells were centrifuged and fixed with ice-cold ethanol (70%), then treated 
overnight with PBS buffer containing RNAse (10 KU/ml) and propidium iodide (PI, 10 
g/ml) (Figure 3.3). When intercalated in DNA, PI fluoresces in the red (620 nm, FL3), 
if it is excited at 488 nm.  
 
G1 
G2/M 
subG1 
S 
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Figure 3.3 Structure of Propidium Iodide (PI) 
 
Each experiment was repeated three times. Samples were analyzed on a Becton Coulter 
Epics XL-MCL flow cytometer. For cell cycle analysis, results were examined using 
MultiCycle for Windows (Phoenix Flow Systems, San Diego, CA).
75
 Data were 
expressed as fractions of cells in the different cycle phases. 
 
3.2.10 TOPOISOMERASE I AND II ASSAY 
 
3.2.10.1 Topoisomerase I relaxation and cleavable complex assay 
 
This assay was adapted from Bridewell et al.179. Incubation mixtures (20 l) conteined 
50 mM Tris-HCl (pH=7.5), 50 mM KCl, 10 mM MgCl2, 0.5 mM dithiothreitol (DTT), 
0.1 mM EDTA, 30 g/ml of BSA, 0.25 g pBR322 supercoiled plasmid DNA and 10 
units of Topoisomerase I. Reactions  were assembled on ice with drug (0-100 M) and 
topoisomerase being added last, incubated at 37°C for 30 min and terminated by the 
addition of pre-warmed SDS (final concentration 1%) followed by proteinase K (final 
concentration 50 g/ml) for an additional digestion at 37°C for 15 min. The reaction 
was terminated by addition of 2 l of loading buffer (0.25% bromophenol blue, 50% 
glycerol).
76
 The samples contained the compounds were successively extracted with 
chloroform and isoamyl alchool (CIA 24:1) prior to load. The reaction mixtures were 
analyzed by electrophoresis on 1% agarose gel in TAE buffer (40 mM Tris-acetate, 
pH=8.0, 1 mM EDTA) at 20 V overnight and then stained with a solution containing 0.5 
g/ml of ethidium bromide. DNA bands were visualized by UV light and photographed 
through a digital photocamera Kodak DC256. 
For the clavable complex assay, the final reaction mixtures were loaded in a 1% agarose 
gel contained 0.5 g/ml of ethidium bromide, run overnight, as previously described, 
and then washed with distilled water. 
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3.2.10.2 Topoisomerase II relaxation assay 
 
Assay mixtures (20 l) contained 100 ng of pBR322 supercoiled plasmid DNA and 2 
units of Topoisomerase II and 0-100 M of selected compounds in aqueos solution 
(50 mM Tris-HCl (pH=8.0), 50 mM KCl, 120 mM MgCl2, 0.5 mM dithiothreitol 
(DTT), 30 g/ml of BSA). The reactions for relaxation assay were carried out as 
described  in section 3.2.10.1. 
 
3.2.10.3 Topoisomerase II cleavable complex assay 
 
Incubation mixtures (20 l) conteined 50 mM Tris-HCl (pH=8.0), 50 mM KCl, 120 mM 
MgCl2, 0.5 mM dithiothreitol (DTT), 0.1 mM EDTA, 30 g/ml of BSA, 0.10 g 
pBR322 supercoiled plasmid DNA and 6 units of Topoisomerase II. Reactions were 
assembled on ice with drug (0-100 M) and topoisomerase being added last, incubated 
at 37°C for 30 min and terminated by the addition of pre-warmed SDS (final 
concentration 0.5%) followed by proteinase K (final concentration 50 g/ml) for an 
additional digestion at 45°C for 1 h. The reaction was terminated by addition of 2 l of 
loading buffer. The samples contained the compounds were successively extracted with 
chloroform and isoamyl alchool (CIA 24:1) prior to load. The reaction mixtures were 
analyzed by electrophoresis on 1% agarose gel in TAE buffer (40 mM Tris-acetate, 
pH=8.0, 1 mM EDTA) at 20 V overnight and then stained with a solution containing 0.5 
g/ml of ethidium bromide. DNA bands were visualized by UV light and photographed 
through a digital photocamera Kodak DC256. 
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4.1 COMPOUNDS 
 
The strategy for the synthesis of 3-aryl-substituted-naphtho[1,2-b]quinolizinium 
derivatives 9, starting from 3-bromo-naphtho[1,2-b]quinolizinium bromide 8, was 
represented by the Suzuki-Miyaura cross-coupling reaction. The desired 3-bromo-
naphtho[1,2-b]quinolizinium bromide 8, lead compound from which to obtain the aryl-
derivatives, was planned to be synthetized from the methyl 6-bromo 2-naphthoate 5 
(Scheme 4.1). At first, the reduction of the methyl ester 5 to alcohol 6a was tried with 
LiAlH4, but the reaction (monitoring by TLC) did not work. In contrast, it was found 
that DIBAL-H is the most effective and selective reagent for this reduction.
66
 The 
bromination was performed with PBr3 and the products of the following reactions were 
used without further purification. By 
1
H-NMR spectroscopy and {1H-1H} COSY 
experiments, it was shown that the angular cyclization of 7b gave the 3-bromo-
naphtho[1,2-b]quinolizinium bromide 8.
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Scheme 4.1 Synthesis of 3-bromo-naphtho[1,2-b]quinolizinium bromide 8. 
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As mentioned before, the synthesis of 3-aryl-substituted-naphtho[1,2-b]quinolizinium 
derivatives 9 was carried out by the Suzuki-Miyaura cross-coupling reaction.
65
 This 
reaction couples an aryl- or vinyl-boronic acid with an aryl- or vinyl-halide and is 
catalyzed by a palladium(0) complex. It is widely used to synthesize poly-olefins, 
styrenes, and substituted biphenyls, and has been extended to incorporate alkyl 
bromides (Scheme 4.2). 
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Scheme 4.2 Suzuki Cross Coupling. 
 
The mechanism of the Suzuki reaction is best viewed from the perspective of the 
palladium catalyst. The first step is the oxidative addition of palladium to the halogen-
carbon of 2 to form the organo-palladium species 3. Ligand exchange with fluoride 
gives intermediate 4, which via transmetalation with the boronate complex 6 forms the 
organopalladium species 8. Reductive elimination of the desired product 9 restores the 
original palladium catalyst 1 (Scheme 4.3).
77,78
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Scheme 4.3 Mechanism of Suzuki-Coupling reaction. 
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These are the derivatives synthesized by Suzuki-Miyaura cross-coupling (Figure 4.1) 
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Figure 4.1 Chemical structures of 3-aryl-substituted-naphtho[1,2-b]quinolizinium derivatives 9. 
 
The counter ion should be the bromine but by the elemental analysis it has been possible 
to evaluate that the purified compounds after column chromatography (Al2O3, Activity 
I) could have chlorine as counter ion. It was shown that quinolizinium salts can 
exchange the counter ion converting it as chlorine after this kind of separation and 
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purification.
79
 So it is reasonable to suppose that also some of 3-aryl-substituted-
naphtho[1,2-b]quinolizinium derivatives could be involved in a similar procedure. 
 
4.2 DNA BINDING PROPERTIES 
 
The association of these compounds with DNA should induce modifications on their 
spectroscopic properties. To investigate the interaction between DNA and compounds, 
it is useful to gain qualitatively and quantitatively information by spectrophotometric 
and spectrofluorimetric titrations; about the orientation of the dye molecule relative to 
the DNA and binding mode, circular (CD) and linear dichroism (LD) spectroscopic 
techniques are useful. Moreover, these spectroscopic methods are advantageous because 
organic dyes absorb and emit at wavelengths that do not interfere with the absorption of 
DNA bases (max ≈ 260 nm). 
 
4.2.1 SPECTROPHOTOMETRIC TITRATIONS 
 
In a complex with DNA, the guest molecule is positioned in an environment which is 
different from that of the uncomplexed compound in solution: thus the two forms can 
have different absorption properties. So, the addition of DNA to a solution of an 
intercalator or groove binder induces a change in the spectrum like a shift of the 
absorption maximum to longer wavelengths (bathochromic shift or red shift) and a 
decrease of the absorbance (hypocromicity).
25
 By these changes, it is possible to study 
the association process of complex compound-DNA adding aliquots of stDNA solution 
to a solution of guest compound and the absorption spectra at each compound-DNA 
ratio were determinated. The experiment was monitored in phosphate buffer 10 mM 
with stDNA and moreover, to avoid secondary effects (charge-charge interactions), the 
titrations were confirmed using a higher ionic strength buffer (ETN 100 mM). 
Compounds 9a, 9b, 9c, 9d, 9e, 9f, 9k have shown a bathochromic shift (Table 4.1) and 
a hypochromic effect and this could indicate an interaction between the dyes and the 
macromolecule.  
 
 
 
  4. Results and discussion 
 
67 
 
 
Table 4.1 Bathochromic shift of compounds 9a, 9b, 9c, 9d, 9e, 9f, 9k. 
 
Compounds max (bathocromic shift) 
9a 11 nm 
 9b 6 nm 
9c 12 nm 
9d 8 nm 
9e 9 nm 
9f 8 nm 
9k 8 nm 
 
 
It was not possible to evaluate the compounds 9g, 9h and 9j because of their low 
solubility in phosphate buffer 10 mM, ETN 10 mM and 100 mM at same concentrations 
of the other compounds; moreover, compounds 9g, 9h, 9i, 9j have shown a non-specific 
effect due to their absorption to the cuvette walls so that a possible decrease of 
absorbance could be due to this and not to interaction with DNA. In order to investigate 
the interaction of these compounds with DNA, circular and linear dichroism can give 
other informations. 
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Figure 4.2 Spectrophotometric titrations of stDNA (0-0.1 mM) to compounds 9a, 9b, 9c, 9d, 9e, 9f, 9k at 
a ligand concentration of 10 M in phosphate buffer at 25°C. Arrows indicate the changes of the intensity 
of the absorption upon addition of stDNA. 
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For compounds 9a, 9b, 9c, 9d, 9e, 9f, 9k, the bathochromic and hypochromic effects 
(Figure 4.2) demonstrate that an interaction with DNA takes place. Isosbestic points are 
generally present for almost all compounds and reveal that each absorption spectrum 
arises from almost exclusively species (complexed and uncomplexed dye). Because it is 
likely that each binding mode results different absorption properties, an isosbestic point 
indicates that mainly one particular binding mode between the DNA and the guest 
molecule occurs. 
 
4.2.2  SPECTROFLUORIMETRIC TITRATIONS 
 
If an uncomplexed molecule has fluorescence emission properties in a solution, the 
addition of DNA can determinate changes in the spectrum, as in the spectrophotometric 
titration.
25
 If there is interaction with DNA, an increasing or decreasing of intensity of 
maximum of fluorescence, or a shift of this, could take place. It must be consider that 
the absorption at a particular wavelength also changes on the DNA addition, which also 
leads to a modification of the emission intensity on excitation at this wavelength; so, to 
avoid this secondary effect, the fluorophore should be excited at the isosbestic point 
obtained by spectrophotometric titrations, and to carry out the experiment in this 
condition. In addition to the information about the interaction between macromolecule 
and dye, by spectrofluorimetric titrations it was possible to obtain quantitative data 
about the formation of the complex dye-DNA, because the fluorimetric technique is 
much more sensitive. By this experiment (always in phosphate buffer 10 mM), the 
variation of the spectrum was determined after the addition of increasing aliquots of 
DNA. It was not possible to have precise and reproducible values for compounds 9g, 
9h, 9i, 9j: they have shown non-specific effect because of their absorption to the cuvette 
walls faking the quantitative calculation. Moreover, compounds 9g and 9i have shown a 
low intensity of fluorescence at the same concentrations of the other compounds.  
    
 
 
 
 
 
 
4. Results and discussion  
70 
 
9a              9b 
W avelength (nm)
380 400 420 440 460 480 500 520 540
F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 (
a
.u
.)
0
100
200
300
400
500
  W avelength (nm)
400 450 500 550 600
F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 (
a
.u
.)
0
50
100
150
200
250
 
 
9c              9d 
W avelength (nm)
380 400 420 440 460 480 500 520 540
F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 (
a
.u
.)
0
100
200
300
400
500
W avelength (nm)
380 400 420 440 460 480 500 520
F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 (
a
.u
.)
0
100
200
300
400
500
 
 
9e              9f 
W avelength (nm)
400 450 500 550 600
F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 (
a
.u
.)
0
200
400
600
800
W avelength (nm)
380 400 420 440 460 480 500 520
F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 (
a
.u
.)
0
200
400
600
800
1000
 
 
 
 
 
 
  4. Results and discussion 
 
71 
 
 
9k 
W avelength (nm)
400 420 440 460 480 500 520 540
F
lu
o
re
s
e
n
c
e
 I
n
te
n
s
it
y
 (
a
.u
.)
0
100
200
300
400
500
600
 
 
Figure 4.3 Spectrofluorimetric titrations of stDNA (0-0.5 mM) to compounds 9a, 9b, 9c, 9d, 9e, 9f, 9k at 
a ligand concentration of 0.5 or 1 M in phosphate buffer at 25°C. 
 
The fluorescence of studied derivatives (9a, 9b, 9c, 9d, 9e, 9f, 9k), after DNA addition, 
is significantly quenched (Figure 4.3). A shift of red maximum was not observed. So, 
this technique has shown that there is an interaction between dye and macromolecule. 
All these data can be utilized to determine quantitative parameters (for detailed 
description see Experimental procedures, section 3.2.2.3) and they are exploited to 
obtained the Scatchard plot;
80
 by binding analysis of the experimental data is performed 
according to the McGhee and Von Hippel model,
69
 it was possible to determinate the 
association constant (K) and the binding site-size (n). All compound, compared to the 
naphthoquinolizinum bromide 2
31
, have shown high binding constants (Table 4.2), also 
producing in most of cases an improvement, confirming a higher affinity to DNA.  
The binding-site size (n) is a measure of the binding sites (base pairs) occupied by one 
guest molecule and gives additional information about the binding mode, according to 
the neighbour-exclusion principle, an intercalator occupies two binding sites, so that at 
full saturation, an alternating sequence of occupied and free binding sites is observed. 
So, an intercalator shows a value n = 2; when n is significantly larger than 2, the test 
compound could be a groove binder. The derivatives analyzed show a possible 
intercalation binding mode (the value of (n) for the compounds is from 1.6 to 2.3). Only 
compound 9f has (n) value > 2, but for similar structure the hypothesis of intercalation 
system is preferred. So, according to this data, the substituent in pos.3 could have 
chemical influence on the tetracyclic structure, increasing the ability of the compound to 
interact with DNA. 
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Table 4.2. DNA binding constants (K), binding-site size (n) of the studied derivatives by fluorimetric 
titrations.  DNA binding constants (K), binding site size (n) of compound 2 is known by literature.
31
 
 
Compounds K (10
5
 M
-1
)
a 
n / bp
b 
9a 4.87 ± 1.5 1.6 ± 0.2 
9b 6.80 ± 2.0 2.1 ± 0.1 
9c 7.08 ± 0.6 1.8 ± 0.1 
9d 2.68 ± 0.2 2.3 ± 0.1 
9e 10.04 ± 0.1 2.2 ± 0.4 
9f 5.74 ± 0.4 4.8 ± 0.6 
9k 1.45 ± 0.4 2.3 ± 0.1 
2
c 
1.90 ± 0.1 2.6 ± 0.1 
 
 
 a
 Apparent binding contstans. 
b 
Binding-site size (in base pairs) calculated from fitting according to the 
McGhee and von Hippel model. 
c
 From ref.31 and from spectrophotometric titration with ctDNA. 
 
 
4.2.3 LINEAR DICHROISM SPECTROSCOPY 
 
Linear dichroism is defined as the differential absorption of linearly polarized light and 
is useful for determination of the binding mode of a dye-DNA complex. DNA is 
composed of aromatic molecules (bases) stacked vertically and twisted about a helix 
axis. The accessible DNA transitions are π-π* transitions of these bases, whose 
absorption starts from about 300 nm and runs down into the far UV. When ligands bind 
to DNA, they may: 
 
 Intercalate between the DNA bases, in which case their π-π* transitions are 
parallel to those of the DNA bases and their LD signals are the same as those 
of the local DNA bases. 
 Bind along the minor groove, in which case their long axis transition are 45˚ 
from the helix axis, with positive LD signals, and their short axis transitions 
line parallel to the DNA bases, with negative LD signals. 
 Bind in the major groove, where geometry constraints are less rigid (Figure 
4.4). 
 Associate non-specifically with the DNA backbone, in which case the LD 
signal will be very small or zero. 
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Figure 4.4 Binding modes of small molecules with DNA 
 
In a hydrodynamic field most of the DNA molecules are partially arranged along the 
flow lines (with the transition moment of DNA bases that has a 90° angle () with 
respect to the reference axis, the direction of hydrodynamic field), so that the DNA 
bases afford a clear negative LD signal (  ≈ 260 nm). Because of their coplanarity, 
intercalators should usually give a negative LD signal; in contrast a groove binder 
should give a positive signal (Figure 4.5), which is relatively weaker compared with that 
of a intercalator.
70,71
  
 
Figure 4.5 Generation of LD signals for an intercalator and a groove binder. 
 
Analyzing these compounds, LD signals of complex dye-DNA are negative at different 
ligand-to-DNA ratios, in the DNA absorption region (molecule stiffening, better 
orientation of the double helix along the flow lines and increasing of negative signal) 
and in the region where only molecules absorb (300-500 nm) (Figure 4.5); the negative 
LD signals in this long-wavelength region indicate that the ligands are coplanar with the 
nucleic bases upon binding with DNA. In the LD spectra, the signal of the intensity of 
DNA increases on addition of compounds, becoming most intensive increasing the 
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compound/DNA ratio; this effect could reflect a stiffening of the DNA helix due to 
intercalation, which results in a better orientation of the macromolecule in the 
hydrodynamic field. Furthermore, all analyzed compounds show a negative signal in the 
region of ligand absorption, typical of intercalation, which becomes more intensive 
when the compound/DNA ratio increases and that demonstrates the intercalation. For 
the compounds 9a, this signal is more intensive, but also for 9c, 9e, 9f and 9i the 
perturbation of the band is significant, so it is possible to hypothesize a strong 
interaction of these molecules with DNA (Figure 4.6). 
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Figure 4.6 Absorption, linear dichroism (LD) and reduced LD (LDr) spectra of all compounds in the 
presence of stDNA (0.75 mM) in phosphate buffer at different ligand-to-DNA ratios (r = 0, 0.02, 0.04, 
0.08, 0.2). Arrows indicate the changes of LD signals at different ligand-to-DNA ratios. 
 
 
The “reduced” linear dichroism (LDr) is obtained by dividing the LD value by the 
absorbance of the unoriented sample. The LDr spectra of dye-DNA complexes can give 
informations about the orientation of the molecular plane of the aromatic dye relative to 
the DNA bases and allow to distinguish between homogeneous and heterogeneous 
binding. The negative LDr signal of compounds 9a, 9c, 9d, 9g, 9i, 9j,  is almost 
independent from the wavelength in the dye-absorption region (300-450 nm, 500 nm) 
which confirms an intercalative binding mode (Figure 4.6).
31
 For compounds 9b, 9e, 9f, 
9h, 9k, the LDr spectra show that the values are not totally constant in that region, 
exhibiting a deviation from perfect intercalation into the double helix: it is conceivable 
an inhomogeneous binding; anyway for all compounds, there is an additional binding 
mode (presumably the outside stacking) with a different orientation of the compound as 
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well as the principal intercalative binging. This different behavior could be due to the 
different influence that the substituent in pos. 3 makes in the naphtho[1,2-
b]quinolizinium 2 structure. 
 
4.2.4  CIRCULAR DICHROISM 
 
Circular dichroism (CD) is defined to be the differential absorption of the right and left-
handed circularly polarized light. It is not observed for achiral molecules, but when they 
form complexes with DNA, they are placed within a chiral environment and give an 
induced CD signal (ICD). The induced CD can derive from a non-covalent interaction 
between the bound compound and the double helix of DNA, so, its presence, confirms 
the compound-DNA interaction and might provide further information about the 
position of the molecule in its complex with the double helix. Although an intercalator 
shows a negative ICD signal and a groove binder a strong positive ICD signal, there are 
many experimental data that prove the opposite theory. Generally an intercalator usually 
has a weak and negative ICD signal, when its transitions are polarized along the long 
axis of the intecalation pocket, or positive ICD, for transitions in the intercalator plane 
that are perpendicular to the intercalator-pocket long axis.
25 
So, to gain the correct 
results, it is necessary before to give a proper interpretation of the spectra ad then 
compare them to other type of investigation.
71,72
 
Aqueous solution of achiral acridizinium salts does not show CD activity, while B-DNA 
shows a spectrum characterized by a negative band at≈ 240 nm and a positive one at 
 ≈ 270. These bands of the DNA region can exhibit a perturbation in the presence of 
increasing concentrations of dyes; but, in order to evaluate an interaction compound-
DNA, the presence of signal (ICD signal) in the region of absorption of ligand (300-500 
nm) is important.  
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Figure 4.7 CD spectra (ICD part) of the compounds in presence of ctDNA (0.89 mM) in phosphate 
buffer at different ligand-to-DNA ratios (0, 0.08, 0.2). Concentrations of ligand alone 10 M. Arrows 
indicate the changes of LD signals at different ligand-to-DNA ratios. 
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The ICD spectra of all derivatives (Figure 4.7) show a weak negative ICD signal 
(usually from 380-450 nm) and a more important positive ICD signal in correspondence 
of the maximum of absorption of the compound (about from 320-350 nm). This signal 
can be more intensive for compounds 9a, 9h,and 9i. Only for compound 9k, the ICD 
bands are very weak. In comparison to the spectrum of naphtho[1,2-b]quinolizinium 
2,
31
 in which the positive ICD signal has been shown a consequence of an intercalation 
system and in relationship to the structure of molecule, the positive ICD signal of 
studied compounds confirms an interaction of intercalative type with the double helix. 
So, this positive ICD signal shows that the transition moments of the intercalated salt 
(and thus approximately the long axis of the chromophore) are aligned almost 
perpendicular to the long axis of the pair-bases pocket. Also considering the negative 
ICD, an additional binding mode could take place, probably due to the presence of the 
substituent in pos.3, although the intercalation is the most important binding mode that 
occurs between the compounds and the nucleic acids. 
 
4.2.5 DNA-PHOTOCLEAVAGE 
 
It is known that the intercalation of planar polycyclic aromatic molecules into double 
stranded DNA leads to a hindered or suppressed function of the nucleic acid in 
physiological processes; furthermore, some of these intercalators agents have shown  to 
be also photosensitizers against nucleic acids, because the light can be used then as a 
trigger for the nuclease activity, representing another kind of damage to DNA. While 
the association of heterocycles compounds to DNA, and thus the DNA modification, is 
reversible process, the DNA damage, which occurs on irradiation of drug-DNA 
complexes, is often irreversible. So, this kind of DNA damage often leads to cell death 
or mutations, and must be avoided in healthy system. However, it may be applied in 
photochemotherapy to remove unwanted cells.
31 
The DNA photocleavage activity of synthesized derivatives was investigated by 
electrophoresis on agarose gel (1%); the compounds were irradiated, in aqueous 
phosphate buffer 10 mM in presence of pBR322 plasmid at different  
[compound]/[DNA] ratios and at increasing UV-A doses (3,75 e 7,5 J cm
-2
). 
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Figure 4.8 Strand breaks of plasmid DNA pBR322 expressed as percentage of form I after UV-A 
irradiation in the presence of the different compounds at increasing [Dye]/[DNA] ratios (r = 0.5, 1, 1.5). 
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The results show no DNA cleavage for all compounds (Figure 4.8) in the experiments in 
“dark condition”. Increasing of concentrations of analyzed derivatives and UV-A 
irradiation dose induce breakage in the nucleic acids structure: there is a decrease of the 
percentage of supercoiled DNA, identifying an hypothetic photodamage. The pBR322 
aliquots irradiated in the presence of compounds at ratio r = 0.5 usually show a weak 
photodamage; but if the ratio increases (r = 1.5), photodamage is very evident. This 
happens quantitatively for compounds 9b, 9c, 9d, 9e, 9f, 9g, 9h, 9j; but for compounds 
9a, 9c, 9k and the reference (2) this behaviour is not so evident. For compounds that act 
provoking a better photodamage, their substituents probably induce a better ability of 
binding to macromolecule or a better photo-activation. 
 
4.2.6 CONCLUSIONS ON DNA BINDING PROPERTIES 
 
In summary, the 3-substituted-naphtho[1,2-b]quinolizinium derivatives 9 have shown a 
strong interaction with DNA-double helix. The introduction of fourth aromatic ring, in 
comparison to the tricyclic benzo[b]quinolizinium 1
31
 and the introduction of the 
substituent in pos. 3 in comparison to the naphtho[1,2-b]quinolizinium 2 have improved 
the interactions between the dye and the DNA bases producing higher binding 
constants. This effect is due to the additional benzene moiety which extends the surface 
of the planar chromophore and increases the  stacking between the dye and the DNA, 
while the substituent in pos. 3 could has chemical influence on the tetracyclic structure, 
increasing its ability to interact with DNA or producing an external binding. However, it 
is difficult to establish which chemical change in the substituent (presence of 
heteroatoms in the ring, introduction of different chemical groups, etc..) leads to 
improved DNA affinity. The results of the LD and CD experiments are generally in 
agreement and reveal a principal intercalative binding mode, not excluding the 
hypothesis of an additional binding mode (presumably the outside stacking). All 
experiments of DNA-binding are in agreement about the interaction of these derivatives 
with DNA: it could happen that the tetracycle is involved in the intercalation with the 
DNA base pairs, whereas the remaining substituent points outside the intercalation 
pocket. Finally, the experiments about the DNA-photocleavage have shown that after 
UV-A irradiation, there is an evident breakage in the nucleic acids structure. 
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4.3 BIOLOGICAL ACTIVITY 
 
4.3.1 CELLULAR CYTOTOXICITY 
 
About the cellular toxicity, two kinds of experiments were considered: before, MTT test 
was useful to evaluate the cytotoxocity by an metabolic inhibition; then Trypan blue test 
was useful to discriminate the growth inhibition from the dead cells.   
 
4.3.1.1 Evaluation by MTT test 
 
Various human tumor cell lines were tested, both leukemic and solid tumor, as: Jurkat 
are human lymphoblastic cells; K562 are chronic myelogenous leukemia, CEM are 
human T lymphoblastic cells, RS 4;11 are human lymphoblastic leukemia cells, SEM 
are human lymphoblastic leukemia cells, MV 4;11 are monocytic acute leukemia cells, 
MCF-7 are human breast carcinoma cells; A549 are human lung carcinoma cells, A431 
are human epidermic carcinoma, HeLa are human cervix carcinoma cells, HT29 are 
colon adenocarcinoma cells. The cells were treated with increasing concentrations of 
the derivatives (20, 10, 5, 2.5, 1.25, 0.625 M) and cytotoxicity was evaluated after 72 h 
of incubation by MTT test.
74
 MTT is a yellow dye that can be absorbed by cells and 
reduced by mitochondrial dehydrogenases, producing insoluble blue crystals, which 
after incubation (3 h) are solubilized and the absorbance detected at  = 570 nm  All 
compounds synthesized were tested and naphtho[1,2-b]quinolizinium bromide 2, 
without substituent in pos. 3 was used as reference compound; cytotoxicity was 
calculated as GI50 micromolar  values (Table 4.3) 
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Table 4.3 Cytotoxicity of the tested compounds against different human tumor cell lines. 
 
IC50 (M)
a
 
Compounds  JURKAT  RS 4;11 K562 CEM SEM MV 4;11 
9a 0.86 ± 0.18 0.31 ± 0.06 1.59 ± 0.11 1.41 ± 0.27 0.54 ± 0.12 0.68 ± 0.19 
9b 0.87 ± 0.13  0.26 ± 0.03 1.34 ± 0.19 1.30 ± 0.34 1.00 ± 0.16 0.40 ± 0.12 
9c 4.10 ± 1.10 0.91 ± 0.18 2.53 ± 0.31 1.52 ± 0.48 1.80 ± 0.52 1.24 ± 0.20 
9d 0.78 ±0.12 0.79 ± 0.09 1.57 ± 0.20 1.57 ± 0.22 1.90 ± 0.37 1.50 ± 0.19 
9e 2.3 ± 0.55 0.20 ± 0.04 2.25 ± 0.24 2.72 ± 0.44 0.84 ± 0.13 0.51 ± 0.16 
9f > 20 > 20 > 20 > 20 > 20 19.2 ± 3.2 
9g 0.84 ± 0.10 0.21 ± 0.07 3.33 ± 0.52 1.34 ± 0.15 0.31 ± 0.05 0.35 ± 0.05 
9h 3.29 ± 0.39 0.71 ± 0.16 5.26 ± 0.31 2.55 ± 0.23 0.82 ± 0.44 1.00 ± 0.30 
9i 9.95 ± 0.32 0.37 ± 0.05 > 20 7.33 ± 0.26 4.80 ± 1.40 3.90 ± 0.80 
9j 0.97 ± 0.10 0.90 ± 0.15 5.67 ± 0.44 2.67 ± 0.13 0.67 ± 0.11 2.90 ± 0.50 
9k > 20 > 20 > 20 > 20 > 20 19.8 ± 2.5 
2
b 
4.98 ± 0.20 14.4 ± 2.2 13.47 ± 1.5 4.80 ± 0.50 > 20 18.6 ± 2.3 
 
Compounds A549 MCF-7 HeLa HT29 A431 
9a 0.20 ± 0.11 5.53 ± 0.44 0.72 ± 0.34 0.83 ± 0.32 4.99 ± 1.00 
9b 1.10 ± 0.24 4.70 ± 0.47 1.30 ± 0.55 1.40 ± 0.22 4.60 ± 0.63 
9c 3.70 ± 1.70 6.44 ± 0.32 3.90 ± 1.00 1.90 ± 0.28 6.78 ± 0.65 
9d 5.50 ± 1.20 4.05 ± 0.59 1.10 ± 0.29 1.10 ± 0.30 6.21 ± 0.69 
9e 2.80 ± 0.80 5.71 ± 0.70 0.74 ± 0.53 3.10 ± 0.81 6.60 ± 0.72 
9f 3.40 ± 1.30 > 20  10.1 ± 3.20 > 20 > 20 
9g 0.96 ± 0.13 1.42 ± 0.11 0.61 ± 0.02 0.70 ± 0.20 5.76 ± 0.40 
9h 2.40 ± 0.24 2.72 ± 0.49 4.50 ± 0.40 3.10 ± 0.60 > 20 
9i 13.5 ± 0.67 10.17 ± 0.62 > 20 10.2 ± 3.10 > 20 
9j 1.20 ± 0.25 1.91 ± 0.10 0.98 ± 0.26 1.10 ± 0.20 9.92 ± 0.51 
9k 2.40 ± 0.70 > 20 > 20 12.6 ± 1.1 > 20 
2
b 1.71 ± 0.20 4.40 ± 0.60 > 20 > 20 > 20 
 
a
 Concentration of compound required to inhibit the cell growth by 50% after 72 h of exposure as 
determined by MTT assay.
74 
 
b 
For compound 2, the cytotoxicity on Jurkat, K-562, CEM, A549, MCF-7 is 
known by literature.
81 
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Almost all derivatives show a micromolar GI50 concentration. On some leukemic cell 
lines, for the compounds 9a, 9b, 9d, 9g and 9j, the GI50 is below the micromolar. The 
compounds 9f and 9k are both only active on A549; moreover 9f is active only on HeLa 
and 9k only on HT29. This could be explained by the characteristics of compounds or 
of the cell line, probably for different molecular target or different cellular uptake.  
Moreover, these two compounds have a similar substituent in pos.3: so the introduction 
of a heterocyclic substituent containing nitrogen decreases the cytotoxic activity 
because of a reduced ability of the molecule to interact with molecular target or of a 
reduced ability to get it. Anyway, for almost all 3-aryl derivatives, the cytotoxicity is 
stronger than the reference compound 2: these data could show that the introduction of 
phenyl group (9a), a phenyl group with a electron donor group in para position in the 
ring, like a dimethyl-amino group (9g) or a methoxyl group (9b), a thiophene group (9e) 
in pos. 3, increases cytotoxic activity; furthermore, about the methoxyl group, the same 
previous hypothesis can be formulated comparing compounds 9h and 9j; the second 
one, which has a -OCH3 group in pos 6’ on the naphthalene structure, shows a higher 
cytotoxicity than the first one, which has not a substituent in the naphthalenyl group.  
Finally, the presence of three electron donor groups (9i) in the phenyl ring seems to 
decrease the cytotoxicity. For the successive experiments on biological activity, 9a, 9b, 
9d, 9g and 9j were chosen because of their low concentration of GI50. 
 
4.3.1.2 Evaluation by Trypan blue test 
 
The trypan blue test allows to distinguish quantitatively inhibition growth and the dead 
cells: it is a dye that is able to pass the cellular membrane of dead cells, giving the 
typical blue coloration, but not of viable cells that will remain white: in the counting by 
microscope, both types of cells will be considered.
82
 The experiment was carried out on 
Jurkat cell line testing compounds 9a, 9b, 9d because their low concentration of GI50; 
the cells were treated with increasing concentrations of the derivatives (10 M, 5 M, 
2.5 M): the cytotoxicity, counting viable cells (white) and dead cells (blue), was 
evaluated after 0 h, 24 h, 48 h and 72 h. 
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Figure 4.9 Number of viable cells and % of dead cells from 0 to 72 h of compounds 9a, 9b and 9d. 
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From these results (Figure 4.9), for the analyzed compounds, the proliferation of viable 
cells is strongly slowed; about the dead cells, the percentage is higher at 72 hours, also 
reaching 30% (compound 9d); although this percentage is significant, is reasonable to 
suppose that compounds mainly act by inducing a cytostatic effect.  
 
4.3.2 CELLULAR PHOTOCYTOTOXYCITY 
 
In order to evaluate if it is possible to improve the biological activity after UV-A 
irradiation, experiments of cellular phototoxicity on leukaemic Jurkat cell line were 
carried out; the cells were treated with increasing concentration of compounds (10, 5, 
2.5, 1.25 M) solubilized in HBSS aqueous buffer and then irradiated with two UV-A 
doses (En = 2.5 J/cm
2
 and 3.75 J/cm
2
) (Table 4.4).  
 
Table 4.4 Photocytotoxicity of the tested compounds against Jurkat cell line. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
 Concentration of compound required to inhibit the cell growth by 50% after 30 minutes of exposure as 
determined by MTT assay after 72 h.
74 
 
b
 UVA dose expressed in J/cm
2
 as measured at 365 nm with a 
Cole-Parmer radiometer.  
IC50 (M)
a 
Jurkat 
Compounds  2,5 J/cm
2b 
3,75 J/cm
2 
9a 1.97 ± 0.22
 
0.95 ± 0.30 
9b 1.33 ± 0.30 0.95 ± 0.13 
9c 2.60 ± 0.21 1.79 ± 0.02 
9d 1.57 ± 0.22 1.24 ± 0.14 
9e 2.48 ± 0.14 1.81 ± 0.19 
9f 3.25 ± 0.24 1.51 ± 0.16 
9g 3.30 ± 0.22 2.46 ± 0.27 
9h 1.90 ± 0.38 1.78 ± 0.17 
9i > 10 > 10 
9j 2.57 ± 0.57 2.48 ± 0.09 
9k > 10 > 10 
2
 
> 10 > 10 
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The photocytotoxicity was evaluated, after 72 h from irradiation, by MTT test
74
 and 
calculated as GI50 micromolar values. As reference compound was used naphtho[1,2-
b]quinolizinium bromide 2, without substituent in pos. 3. Compounds 9c, 9e, 9f, 9h 
have shown an improvement of cytotoxic activity: this could be due to the effect of UV-
A irradiation. For the remaining compounds, the UV-A irradiation does not increase 
antiproliferative activity: this behavior could depend on the different nature of 
substituents and their role in the photoactivation process or simply on the fact that they 
did not enter the cells for the brief period of incubation before irradiation (30 min). 
 
4.3.3 INTRACELLULAR LOCALIZATION 
 
The cellular localization of the compounds is evaluated to check the distribution of 
molecules inside cells to clarify the eventual cellular structure involved in the cytotoxic 
action. In order to investigate the intracellular localization (due to physicochemical 
properties such as hydrophobicity, charge interactions, etc.) of quinolizinium 
derivatives through confocal microscopy, HeLa cells were incubated at 37°C in the 
presence of compounds 9g and 9j (10 M). After 1-2 h (Figure 1.10), a general 
diffusion in the cytoplasmatic compartment is evident and this fact confirms that the 
compounds enter inside the cell causing the cytotoxic effect. 
 
  
    A               B 
 
Figure 4.10 Fluorescence images showing the intracellular localization of 9g (panel A) and 9j (panel B) 
in HeLa cells. 
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4.3.4  ANALYSIS OF CELL CICLE 
 
Many antiproliferative drugs are able to block one particular phase of cell cycle (G1, S 
or G2/M phase). Then, the cells can repair the damage induced by a exogenous 
molecule and they return into the cycle (from G0 to G1), or if there is permanent 
damage, they can undergo apoptosis or necrosis. This analysis was conducted by flow 
cytometry and the different content of cellular DNA in each phase is evaluated. A 
typical diagram of growing cultures displays a first peak corresponding to G1 phase, a 
second peak characteristic of G2/M phase with an intermediate area corresponding to 
the S phase. When DNA is fragmented, as in apoptotic cells, a phase sub-G1 
(hypodiploid peak) becomes apparent on the left of G1 peak. (For details see also 
section 3.2.9.1) 
A549 cells were treated with compounds 9a, 9b and 9d at concentrations 10, 5, 2.5  
M; Jurkat cells were treated with compounds 9a, 9b, 9d and 9h; HeLa cells were 
treated with compounds 9a, 9b, 9d, 9g and 9h. After 24 h of incubation, the cells were 
marked with PI, which intercalates into DNA giving a fluorescence in the red (620 nm) 
if it is excited at 488 nm. 
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Figure 4.11 Percentage of A549 cells in the different phases of cell cycle after 24 h of incubation with 
compounds 9a, 9b, 9d. Ctr = control cells not treated. 
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Figure 4.12 Percentage of Jurkat cells in the different phases of cell cycle after 24 h of incubation with 
compounds 9a, 9b, 9d, 9h. Ctr = control cells not treated. 
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Figure 4.13 Percentage of HeLa cells in the different phases of cell cycle after 24 h of incubation with 
compounds 9a, 9b, 9d, 9g and 9h. Ctr = control cells not treated. 
 
 
A weak increase of percentage of cells in G1 phase is evident for all compounds and all 
concentrations in comparison to the control cells (not treated cells) in A549 cell line 
(Figure 4.11). In Jurkat cells, this effect can be observed only for compound 9h (Figure 
4.12); for the other ones, no changes in the cell cycle are present and the same thing 
happens in HeLa cells (Figure 4.13). 
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4.3.5 TOPOISOMERASE I AND II ASSAY 
 
Topoisomerase are important enzymes about the resolution of topological problems in 
DNA, such as overwinding, underwinding, catenation, which arise during replication, 
transcription and other biochemicals DNA processes. In eukaryotic cells, two type of 
topoisomerase have been identified (I and II): their action is the formation of enzyme-
bridged strand-breaks (topoisomerase I breaks one strand duplex DNA, topoisomerase 
II breaks both strands of the double helix) that act as transient gates for the passage of 
other DNA strands. After that, the religation takes place and the final result is the 
introduction of negative or positive supercoils into the DNA. Topoisomerase-targeting 
drugs appear to interfere with the breakage-reunion of DNA, by the production of a 
ternary aborted reaction intermediate, the “cleavable complex”, that inhibits the 
religation. As result of this action, drugs “poison” of topoisomerase could be converted 
in cellular toxins that generate breaks and degradation of the genetic materials of treated 
cells. This action and its cellular effects could be useful in the identification and in the 
development of new anticancer molecules. 
 
4.3.5.1 Inhibition of topoisomerase I 
 
The ability of the antitumor agent coralyne to stabilize the “cleavable complex” 
between topoisomerase I and DNA was demonstrated,
44
 so coralyne was chosen as 
reference compound because its structural analogy with quinolizinium derivatives and 
naphtho[1,2-b]quinolizinium bromide 2 was chosen to clarify the role the substituent in 
pos. 3. Firstly, the ability of compounds 9a, 9b, 9d, and 9g to act as catalytic inhibitors 
was analyzed by horizontal electrophoresis with a agarose 1% gel in absence of 
ethidium bromide. In a second time, their capability of stabilizing the cleavable 
complex was checked by agarose 1% gel containing 0.5 g/ml of ethidium bromide. In 
order to clarify and to find the molecular target, the possible action on topoisomerase I 
of compound 9f, which is not cytotoxic on the most of the treated cell lines, was 
evaluated. The compounds were incubated at increasing concentrations (0.1 - 100 M)  
with supercoiled pBR322 and human Topoisomerase I. 
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Figure 4.14 Effects of increasing concentrations of selected compound on topoisomerase I. Panel A: 
relaxation assay. The supercoiled plasmid pBR322 (lane pla) was incubated with topoisomerase I in the 
absence (lane Topo I) and in presence of compounds at indicated concentrations. Reactions were stopped 
with SDS and treatment with proteinase K. DNA samples were separated by electrophoresis on agarose 
gel and the stained with a solution containing ethidium bromide. F I = form I, supercoiled; F II = form II, 
nicked-open circular. Panel B: cleavable complex assay. The supercoiled plasmid pBR322 (lane pla) was 
incubated with topoisomerase I in the absence (lane Topo I) and in presence of drugs at indicated 
concentrations. Reactions were stopped with SDS and treatment with proteinase K. DNA samples were 
separated by electrophoresis on agarose gel containing ethidium bromide. F I = form I, supercoiled; F II = 
form II, nicked-open circular; Form IV = form IV, relaxed. 
  
 
From the analysis of agarose gels without ethidium bromide (Figure 4.14, Panel A), all 
compounds act, in different concentrations, as catalytic inhibitor towards topoisomerase 
I, making a block in the cut of DNA by enzyme: there is the presence of form F II 
(nicked-open circular) and of the topoisomers in respect with the form FI (supercoiled) 
until determined concentrations; in respect with the references, that are coralyne and 
naphtho[1,2-b]quinolizinium bromide 2 (for both inhibition at 25 M), the compound 
a shows the most important catalytic inhibition, about at 10 M; b shows a relaxation 
inhibition at 25 M. The compounds 9d and 9g show a relaxation block at 100 M. 
Moreover, it is interesting to evaluate that the compound 9f, weakly cytotoxic on almost 
all cell lines, shows, as previously compounds, a catalytic block at 100 M. From the 
analysis of agarose gels in presence of ethidium bromide (Fig 4.14 Panel B), the 
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compounds do not act as poisons toward the enzyme: there is not a clear presence of the 
form “nicked” (Form II), because the compounds do not block the DNA religation 
activity of the enzyme, except of compound 9a and 9d but this happens just at high 
concentration (100 M) in respect with the form FIV (relaxed). 
Catalytic inhibition, although in concentrations higher than GI50 calculated by MTT test, 
could be explained by a hypothetic mechanism about which the 4-rings-structure 
intercalates in DNA with consequent block of binding of the enzyme to the nucleic acid. 
Only compounds 9a shows a stronger relaxation inhibition: so, is reasonable to suppose 
that the presence of a determined substituent in pos. 3 could increase the ability of 
molecule to inhibit the enzyme. 
 
4.3.5.2  Inhibition of topoisomerase II 
 
Some experiments are carried out in order to verify an eventual interaction with 
topoisomerase II, because it is known from literature that there are molecules that 
interact with DNA that can inhibit both enzymes. As reference compound was chosen 
etoposide,
48
 because its ability to inhibit topoisomerase II is known by literature. 
Naphtho[1,2-b]quinolizinium bromide 2 was also chosen as reference compound to 
evaluate the role of the substituent in pos. 3. 
Compounds 9a, which showed better cytotoxicity and better ability to produce a 
catalytic inhibition of topoisomerase I, was tested for the relaxation assay and cleavable 
complex assay. Compounds 9g and 9j were tested only for the relaxation assay.  
For the relaxation assay, supercoiled plasmid pBR322 was incubated with human 
topoisomerase II and concentration of 9a, 9g and 9j ranging from 1 to 100 M. The 
reference compounds, etoposide and naphtho[1,2-b]quinolizinium bromide 2 were 
analyzed at 100 M in two different lanes.  
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Figure 4.15 Effect of increasing concentrations of 9a, 9g and 9j on toposiomerase II: relaxation assay. 
Native supercoiled plasmid pBR322 (lane pla) was incubated with 2 units of topoisomerase II in the 
absence (lane topo II) and in the presence of drugs at the indicated concentrations. Etoposide (lane ETO) 
and 2 (lane 2) were used at 100 M. Reactions were stopped with SDS and treatment with proteinase K. 
DNA samples were separated by electrophoresis on agarose gel and then stained with a solution 
containing ethidium bromide. F I= form I, supercoiled; F II=form II, nicked-open circular.  
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The gels shown in figure 4.15 indicate that for compounds 9a, 9g and 9j between the 
concentrations of 10 and 50 M the relaxation of DNA was inhibited, most likely as a 
result of the intercalation of the tetracycle into DNA (as previously observed for 
topoisomerase I). In comparison to the lanes of etoposide and the reference compound 
2, that does not show the presence of topoisomers at 100 M, is reasonable to 
hypothesize that the structure with 4 rings intercalates into DNA and the substituent in 
pos.3 increases weakly the ability of the derivatives analyzed to block the protein, 
decreasing the concentration of inhibition.   
For the cleavable complex assay, supercoiled plasmid pBR322 was incubated with 
human topoisomerase II and concentration of 9a ranging from 1 to 100 M. 
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Figure 5.12 Effect of increasing concentrations of 9a on topoisomerase II: cleavable complex assay. 
Native supercoiled plasmid pBR322 (lane pla) was incubated with 6 units of topoisomerase II in the 
absence (lane topo II) and in the presence of drugs at the indicated concentrations. Etoposide (lane ETO) 
and 2 (lane 2) were used at 100 M. Reactions were stopped with SDS and treatment with proteinase K. 
DNA samples were separated by electrophoresis on agarose gel containing ethidium bromide. F I=form I, 
supercoiled; F II=form II, nicked-open circular; F III=form III, linear.  
 
The gel of the cleavable complex assay (fig. 5.12) reveals that 9a (but also the reference 
compound 2) does not induce permanently breakage, as it can been observed for 
etoposide (form FIII), which makes a stabilization of “clavable ternary complex”. 
Finally, the relaxation inhibition can due to the ability to intercalate into DNA. 
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4.3.6  CONCLUSION ON BIOLOGICAL ACTIVITY 
 
Cytotoxicity experiments have clearly revealed that the introduction of the fourth 
aromatic ring and subsequently of an aryl substituent in pos. 3 on the naphtho[1,2-
b]quinolizinium structure produces a high antiproliferative activity, with micromolar or 
submicromolar GI50 values by MTT test. However, the results of trypan blue test 
together with the absence of subG1 peak in cell cycle profile let me hypothesise a 
cytostatic mechanism. Almost all substituents have shown this improvement with 
optimal results (compounds 9a, 9b, 9g), except heterocycles containing nitrogen 
(compounds 9f, 9k). This low cytotoxicity could be justified by the difficult of these 
two compounds to get the hypothetical molecular target, because in the test without 
involving the cells (DNA binding properties, topoisomerase I inhibition), they have not 
shown a different behaviour compared to the other compounds.  
About the activity against the topoisomerase I, the analyzed compounds have shown a 
relaxation inhibition, but there is not a clear block of religation (except for compounds 
9a and 9d, although this is weak); about the topoisomerase II, the behaviour is the same: 
the relaxation is inhibited, but there is not a stabilization of “cleavable ternary 
complex”. The high antiproliferative activity, confirmed by intracellular localization, 
cannot be justified by the partial inhibition of the topoisomerase I and II; these enzymes 
cannot be the molecular targets, which could instead be represented by the nucleic 
acids. Anyway more detailed studies on the mechanism of action are needed to reveal 
other possible molecular targets. 
About the photobiological activity, only the compounds 9c, 9e, 9f, 9h have shown an 
improvement of cytotoxic activity after UV-A irradiation.  
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